<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2701256762
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Norditropin FlexPro
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SOMATROPIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        6.7
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection in pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        975.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVO NORDISK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 445]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novo Nordisk
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        H01AC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> contains a biosynthetic human growth hormone called somatropin which is identical to the growth hormone produced naturally in the body. Children need growth hormone to help them grow, but adults also need it for their general health.</p><p>&nbsp;</p><p><strong>Norditropin</strong><strong><sup>&reg;</sup></strong><strong> FlexPro</strong><strong><sup>&reg;</sup></strong><strong> </strong><strong>is used to treat growth failure in children</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If they have no or very low production of growth hormone (growth hormone deficiency)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If they have Turner syndrome (a genetic problem which may affect growth)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If they have reduced kidney function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If they are short and were born small for gestational age (SGA)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If they have Noonan syndrome (a genetic problem which may affect growth).</p><p>&nbsp;</p><p><strong>Norditropin</strong><strong><sup>&reg;</sup></strong><strong> FlexPro</strong><strong><sup>&reg;</sup></strong><strong> is used as a growth hormone replacement in adults</strong></p><p>In adults Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> is used to replace growth hormone if their growth hormone production has been decreased since childhood or has been lost in adulthood because of a tumour, treatment of a tumour, or a disease that affects the gland which produces growth hormone. If you have been treated for growth hormone deficiency during childhood, you will be retested after completion of growth. If growth hormone deficiency is confirmed, you should continue treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use </strong><strong>Norditropin<sup>&reg;</sup> FlexPro<sup>&reg;</sup></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are <strong>allergic</strong> to somatropin, to phenol, or to any of the other ingredients of this medicine (listed in section 6)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had a <strong>kidney transplant</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an <strong>active tumour</strong> (<strong>cancer</strong>). Tumours must be inactive and you must have finished your antitumour treatment before you start your treatment with Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an <strong>acute critical illness,</strong> e.g. open heart surgery, abdominal surgery, multiple accidental trauma or acute respiratory failure</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have stopped growing (closed epiphyses) and you do not have growth hormone deficiency.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before using Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have <strong>diabetes</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had a <strong>cancer</strong> or another kind of <strong>tumour</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have recurrent <strong>headaches, eyesight problems, nausea</strong> or if <strong>vomiting</strong> occurs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have abnormal <strong>thyroid</strong> function</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increase in sideways curvature of the spine (scoliosis) may progress in any child during rapid growth. During treatment with Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong>, your doctor will check you (or your child) for signs of scoliosis.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you walk with a limp or if you start to limp during your growth hormone treatment, you should inform your doctor.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are <strong>over 60</strong>&nbsp;<strong>years of age</strong>, or have received somatropin treatment as an adult for more than 5&nbsp;years, as experience is limited</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from <strong>kidney disease,</strong> as your kidney function should be monitored by your physician</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a <strong>replacement therapy with glucocorticoids,</strong> you should consult your doctor regularly, as you may need adjustment of your glucocorticoid dose.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> may cause an inflammation of the pancreas, which causes severe pain in the abdomen and back. Contact your doctor if you or your child develops stomach ache after taking Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong>.</p><p>&nbsp;</p><p><strong>Other medicines and Norditropin</strong><strong><sup>&reg;</sup></strong><strong> FlexPro</strong><strong><sup>&reg;</sup></strong></p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p>In particular, inform your doctor if you are taking or have recently taken any of the following medicines. Your doctor may need to adjust the dose of Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> or of the other medicines:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Glucocorticoids</strong> &ndash; your adult height may be affected if you use Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> and glucocorticoids at the same time</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cyclosporine </strong>(immunosuppressive) &ndash; as your dose may need to be adjusted</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Insulin </strong>&ndash; as your dose may need to be adjusted</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Thyroid </strong>hormone &ndash; as your dose may need to be adjusted</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gonadotropin</strong> (gonad stimulating hormone) &ndash; as your dose may need to be adjusted</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Anticonvulsants</strong> &ndash; as your dose may need to be adjusted</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Oestrogen</strong> taken orally or other sex hormones.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Somatropin containing products are not recommended in women of childbearing potential not using contraception.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pregnancy &ndash;</strong> stop the treatment and tell your doctor if you become pregnant while you are using Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong></p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast-feeding &ndash; </strong>do not use Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> while you are breast-feeding because somatropin might pass into your milk.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> does not affect the use of any machines or the ability to drive safely.</p><p>&nbsp;</p><p><strong>Norditropin</strong><strong><sup>&reg;</sup></strong><strong> contains sodium</strong></p><p>Norditropin<strong><sup>&reg;</sup></strong> contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 1.5 mL, that is to say</p><p>essentially &lsquo;sodium-free&rsquo;.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Recommended dose</strong></p><p>The dose for children depends on their body weight and body surface area. Later in life, the dose depends on your height, weight, gender and growth hormone sensitivity and will be adjusted until you are on the right dose.</p><p><strong>&nbsp;</strong></p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children with low production or lack of growth hormone:</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is 0.025 to 0.035&nbsp;mg per kg body weight per day or 0.7 to 1.0&nbsp;mg per m<sup>2</sup> body surface area per day</p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children with Turner syndrome:</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is 0.045 to 0.067&nbsp;mg per kg body weight per day or 1.3 to 2.0&nbsp;mg per m<sup>2 </sup>body surface area per day</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Children with kidney disease:</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is 0.050&nbsp;mg per kg body weight per day or 1.4&nbsp;mg per m&sup2; body surface area per day</p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children born small for gestational age (SGA):</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is 0.035&nbsp;mg per kg body weight per day or 1.0&nbsp;mg per m<sup>2</sup> body surface area per day until final height is reached. (In clinical trials of short children born SGA doses of 0.033 and 0.067&nbsp;mg per kg body weight per day have typically been used)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Children with Noonan syndrome:</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose is 0.066&nbsp;mg per kg body weight per day, however your doctor may decide that 0.033 mg per kg body weight per day is sufficient.</p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adults with low production or lack of growth hormone:</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your growth hormone deficiency continues after completion of growth, treatment should be continued. The usual starting dose is 0.2 to 0.5&nbsp;mg per day. The dose will be adjusted until you are on the right dose. If your growth hormone deficiency starts during adult life, the usual starting dose is 0.1 to 0.3&nbsp;mg per day. Your doctor will increase this dose each month until you are getting the dose you need. The usual maximum dose is 1.0&nbsp;mg per day.</p><p>&nbsp;</p><p><strong>When to use </strong><strong>Norditropin<sup>&reg;</sup> FlexPro<sup>&reg;</sup></strong></p><p>Inject your daily dose into the skin every evening just before bedtime.</p><p>&nbsp;</p><p><strong>How to use Norditropin</strong><strong><sup>&reg;</sup></strong><strong> FlexPro</strong><strong><sup>&reg;</sup></strong></p><p>Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> growth hormone solution comes in a multidose disposable 1.5&nbsp;mL pre-filled pen.</p><p>Full instructions on how to use Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> are given overleaf. The instructional key points are as follows:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check the solution before use by turning the pen upside down once or twice. Do not use the pen if the solution is cloudy or discoloured (see page 8, step A)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> is designed to be used with NovoFine<strong><sup>&reg;</sup></strong> or NovoTwist<strong><sup>&reg;</sup></strong> disposable needles up to a length of 8&nbsp;mm</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Always use a new needle for each injection</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vary the area you inject so you do not harm your skin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To make sure you get the proper dose and do not inject air, check the growth hormone flow before the first injection from a new Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> pen. Do not use the pen if a drop of growth hormone solution does not appear at the needle tip (see pages 10 to 11, steps E to G)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not share your Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> pen with anyone else.</p><p>&nbsp;</p><p><strong>How long you will need treatment for</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children with growth failure because of Turner syndrome, kidney disease, SGA or Noonan syndrome: Your doctor will recommend you continue treatment until you stop growing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children or adolescents who lack growth hormone: Your doctor will recommend you continue treatment into adulthood</p><p>&nbsp;</p><p>Do not stop using Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> without discussing it with your doctor first.</p><p>&nbsp;</p><p><strong>If you use more Norditropin</strong><strong><sup>&reg;</sup></strong><strong> FlexPro</strong><strong><sup>&reg;</sup></strong><strong> than you should</strong></p><p><strong>Tell your doctor </strong>if you inject too much somatropin. Long-term overdosing can cause abnormal growth and coarsening of facial features.</p><p>&nbsp;</p><p><strong>If you forget to use Norditropin</strong><strong><sup>&reg;</sup></strong><strong> FlexPro</strong><strong><sup>&reg;</sup></strong></p><p>Take the next dose as usual, at the normal time. <strong>Do not take a double dose</strong> to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop using Norditropin<sup>&reg;</sup> FlexPro<sup>&reg;</sup></strong></p><p>Do not stop using Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> without discussing it with your doctor first.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Effects seen in children and adults </strong>(unknown frequency)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Rash; wheezing; swollen eyelids, face or lips; complete collapse.</strong> Any of these may be signs of an allergic reaction</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Headache, eyesight problems, feeling sick</strong> (<em>nausea</em>) and <strong>being sick </strong>(<em>vomiting</em>). These may be signs of raised pressure in the brain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Serum thyroxin</strong> levels may decrease</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hyperglycaemia</strong> (elevated levels of blood glucose)</p><p>If you get any of these effects,<strong> see a doctor as soon as possible</strong>. Stop using Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> until your doctor says you can continue treatment.</p><p>&nbsp;</p><p>Formation of antibodies directed against somatropin has rarely been observed during Norditropin<strong><sup>&reg;</sup></strong> therapy.</p><p>Increased levels of liver enzymes have been reported.</p><p>Cases of leukaemia and relapse of brain tumours have also been reported in patients treated with somatropin (the active ingredient in Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong>), although there is no evidence that somatropin was responsible for this.</p><p>If you think you are suffering from any of these diseases, talk to your doctor.</p><p>&nbsp;</p><p><strong>Additional side effects in children</strong></p><p><strong>Uncommon </strong>(may affect up to 1 in 100 children)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Headache</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Redness</strong>, itching and pain in the area of injection</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Breast enlargement</strong> (gynaecomastia).</p><p><em>&nbsp;</em></p><p><strong>Rare </strong>(may affect up to 1 in 1,000 children)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Rash</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Muscle</strong> and joint pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Swollen hands</strong> and feet due to fluid retention.</p><p>In rare cases, children using Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> have experienced hip and knee pains or have started limping. These symptoms may be caused by a disease affecting the top of the thigh bone (<em>Legg-Calv&eacute; disease</em>) or because the end of the bone has slipped from the cartilage (<em>slipped capital femoral epiphysis</em>) and may not be due to Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong>.</p><p>&nbsp;</p><p>In children with <strong>Turner syndrome</strong>, a few cases of <strong>increased growth of hands and feet</strong> compared to height have been observed in clinical trials.</p><p>&nbsp;</p><p>A clinical trial in children with Turner syndrome has shown that high doses of Norditropin<strong><sup>&reg;</sup></strong> can possibly increase the risk of getting ear infections.</p><p>&nbsp;</p><p><strong>If any of these side effects gets serious</strong>, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist, as the dose may need to be reduced.</p><p><strong>&nbsp;</strong></p><p><strong>Additional side effects in adults</strong></p><p><strong>Very common </strong>(may affect more than 1 in 10 adults)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Swollen hands </strong>and feet due to fluid retention.</p><p><strong>&nbsp;</strong></p><p><strong>Common </strong>(may affect up to 1 in 10 adults)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Headache</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling of <strong>skin crawling</strong> (<em>formication</em>) and numbness or pain mainly in fingers</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Joint pain</strong> and stiffness; muscle pain.</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 adults)</p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Type 2 diabetes</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Carpal tunnel syndrome; </strong>tingling and pain in fingers and hands</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Itching</strong> (can be intense) and pain in the area of injection</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Muscle stiffness</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Breast enlargement</strong> (gynaecomastia).</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>If you get any side effect, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>&nbsp;</p><p><u>Please report side effects to:</u><u> </u></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the package after EXP/. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p><strong>Store unused</strong> Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> pens in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C) in the outer carton, in order to protect them from light. Do not freeze or expose to heat. Do not store close to any cooling elements.</p><p>&nbsp;</p><p><strong>While using</strong> Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> 10&nbsp;mg/1.5&nbsp;mL you can <strong>either:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep it for up to 4 weeks in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C), <strong>or</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep it for up to 3 weeks at room temperature (below 25&deg;C).</p><p>&nbsp;</p><p>Do not continue to use Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> pens if they have been frozen or exposed to excessive temperatures.</p><p>&nbsp;</p><p>Do not use Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> pens where the growth hormone solution is cloudy or discoloured.</p><p>&nbsp;</p><p>Always store Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> without a needle attached.</p><p>Always keep the pen cap fully closed on the Norditropin<strong><sup>&reg;</sup></strong> FlexPro<strong><sup>&reg;</sup></strong> pen when you are not using it.</p><p>Always use a new needle for each injection.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Norditropin<sup>&reg;</sup> FlexPro<sup>&reg;</sup> contains</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is somatropin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other excipients are mannitol, histidine, poloxamer&nbsp;188, phenol, water for injection, hydrochloric acid and sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Norditropin® FlexPro® looks like and contents of the pack
	Norditropin® FlexPro® is a clear and colourless solution for injection in a multidose disposable 1.5 mL pre-filled pen.
	
	1 mL of solution contains 6.7 mg somatropin.
	1 mg of somatropin corresponds to 3 IU of somatropin.
	
	Norditropin® FlexPro® is available in three strengths:
	5 mg/1.5 mL, 10 mg/1.5 mL and 15 mg/1.5 mL (equivalent to 3.3 mg/mL, 6.7 mg/mL and 10 mg/mL, respectively) in pack sizes of 1 or 5 pre-filled pens. Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong></p><p>Novo Nordisk A/S</p><p>Novo All&eacute;</p><p>DK-2880 Bagsv&aelig;rd, Denmark</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Novo Nordisk A/S</p><p>Hallas All&eacute;</p><p>DK-4400 Kalundborg, Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	11/2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي نورديتروبين فلكس برو على هرمون نمو بشري مُخلّق حيويًا يسمى سوماتروبين الذي يماثل هرمون النمو الذي يفرزه الجسم طبيعيًا. يحتاج الأطفال إلى هرمون النمو لمساعدتهم في النمو؛ بينما يحتاج إليه البالغون أيضًا لصحتهم العامة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُستخدم نورديتروبين فلكس برو لعلاج قصور النمو لدى الأطفال</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم يكن لديهم أي إفراز لهرمون النمو أو إذا كان إفرازه ضعيفًا جدًا (نقص هرمون النمو)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا مصابين بمتلازمة تيرنر (مشكلة وراثية قد تؤثر على النمو)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا مصابين بقصور في وظائف الكلى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا قصار القامة وولدوا صغارًا بالنسبة لسن الحمل (SGA)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانوا مصابين بمتلازمة نونان (مشكلة وراثية قد تؤثر على النمو).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُستخدم نورديتروبين فلكس برو كبديل لهرمون النمو لدى البالغين</strong></p><p dir="RTL">في البالغين، يُستخدم نورديتروبين فلكس برو لاستبدال هرمون النمو إذا كان إفراز هرمون النمو لديهم قد انخفض منذ الطفولة أو قد فقدوه في مرحلة البلوغ بسبب الإصابة بورم، أو علاج ورم، أو إصابة بمرض يؤثر على الغدة التي تفرز هرمون النمو. إذا كنت قد تلقيت علاجًا لنقص هرمون النمو أثناء فترة الطفولة، فستخضع لاختبارات أخرى بعد اكتمال النمو. إذا تم تأكيد إصابتك بنقص هرمون النمو، ينبغي عليك متابعة العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم نورديتروبين فلكس برو</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>حساسية </strong>تجاه سوماتروبين، أو فينول، أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أجريت <strong>عملية زراعة كلى</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا <strong>بورم نشط (سرطان)</strong>. يجب أن تكون الأورام غير نشطة، ويجب أن تكون قد أكملت العلاج المضاد للأورام قبل بدء العلاج باستخدام نورديتروبين فلكس برو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا <strong>بمرض خطير حاد،</strong> مثل جراحة القلب المفتوح، أو جراحة البطن، أو الرضح الحادثي المتعدد أو القصور التنفسي الحاد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان قد توقف نموك (المُشاشات المغلقة) ولم تكن مصابًا بنقص في هرمون النمو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">ينبغي استشارة طبيبك أو الصيدلي قبل استعمال دواء نورديتروبين فلكس برو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا <strong>بداء السكري</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا قبل ذلك بمرض <strong>السرطان</strong> أو نوع آخر من <strong>الأورام</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بحالات متكررة من <strong>الصداع،</strong> أو <strong>مشكلات في الرؤية،</strong> أو <strong>الغثيان </strong>أو إذا كنت تعاني من <strong>التقيؤ</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت <strong>الغدة الدرقية </strong>لا تؤدي وظائفها بشكل طبيعي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث زيادة في انحناء العمود الفقري (الجنف) جانبيًا عند أي طفل خلال النمو السريع. وأثناء العلاج باستخدام نورديتروبين فلكس برو، سيفحصك طبيبك (أو يفحص طفلك) بحثًا عن علامات الجنف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعرج أو إذا بدأت تعرج أثناء العلاج بهرمون النمو، ينبغي عليك إبلاغ طبيبك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا <strong>تجاوز عمرك 60 سنة</strong> أو كنت قد تلقيت علاجًا بسوماتروبين في مرحلة البلوغ لأكثر من 5 سنوات، نظرًا لأن التجربة محدودة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من <strong>مرض في الكلى،</strong> حيث إنه ينبغي مراقبة وظيفة الكلى بمعرفة طبيبك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك <strong>علاج بديل &rlm;‫بالأدوية القشرانية السكرية</strong>، ينبغي عليك استشارة طبيبك بانتظام، حيث قد تحتاج إلى تعديل جرعة &rlm;‫الأدوية القشرانية السكرية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يسبب نورديتروبين فلكس برو التهاب البنكرياس، ما يسبب ألمًا شديدًا في البطن والظهر. اتصل بطبيبك إذا أصبت أنت أو طفلك بألم في المعدة بعد تناول نورديتروبين فلكس برو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى ونورديتروبين فلكس برو</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تستخدم أي أدوية أخرى، أو قد استخدمتها مؤخرًا أو قد تستخدمها.</p><p dir="RTL">وعلى وجه الخصوص، أخبر طبيبك إذا كنت تتناول أو قد تناولت مؤخرًا أيًا من الأدوية التالية. فقد يحتاج طبيبك إلى ضبط جرعة نورديتروبين فلكس برو أو الأدوية الأخرى:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأدوية القشرانية السكرية</strong> - قد يتأثر طول البالغين في حالة استخدام نورديتروبين فلكس برو والأدوية القشرانية السكرية في نفس الوقت</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>السيكلوسبورين</strong> (كابت المناعة) - حيث إنه قد تكون هناك حاجة لتعديل الجرعة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الإنسولين</strong> - حيث إنه قد تكون هناك حاجة لتعديل الجرعة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمون <strong>الغدة الدرقية</strong> - حيث إنه قد تكون هناك حاجة لتعديل الجرعة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غونادوتروبين</strong> (هرمون تنشيط الغدة التناسلية) - حيث إنه قد تكون هناك حاجة لتعديل جرعتك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مضادات الاختلاج</strong> - حيث إنه قد تكون هناك حاجة لتعديل جرعتك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأستروجين</strong> الذي يؤخذ عن طريق الفم أو الهرمونات الجنسية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا يوصى باستخدام المنتجات التي تحتوي على مادة سوماتروبين للنساء اللاتي يُحتمل حملهن بسبب عدم استخدام موانع الحمل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الحمل</strong> - عليكِ بإيقاف العلاج وإخبار طبيبِك إذا أصبحتِ حاملاً أثناء استخدام نورديتروبين فلكس برو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الرضاعة الطبيعية &ndash;</strong> لا تستخدمي نورديتروبين فلكس برو أثناء قيامك بالرضاعة نظرًا لأن مادة سوماتروبين قد تنتقل إلى اللبن لديكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة المركبات واستخدام الآلات</strong></p><p dir="RTL">لا يؤثر نورديتروبين فلكس برو على استخدام أي آلات أو القدرة على القيادة بأمان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي نورديتروبين على الصوديوم</strong></p><p dir="RTL">يحتوي نورديتروبين على أقل من 1 ملي مول صوديوم (23 ملجم) لكل 1.5 مل، أي</p><p dir="RTL">&quot;خالٍ من الصوديوم&quot; في الأساس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم هذا الدواء دومًا كما أخبرك طبيبك تمامًا. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الموصى بها</strong></p><p dir="RTL">تتوقف جرعة الأطفال على وزن الجسم ومساحة سطح الجسم. وكلما تقدم العمر، تتوقف الجرعة على الطول، والوزن، ونوع الجنس وحساسية هرمون النمو، وسيتم تعديلها حتى تصل إلى الجرعة المناسبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال الذين يعانون من انخفاض إفراز هرمون النمو أو انعدامه:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة 0.025 إلى 0.035 ملجم لكل كلجم من وزن الجسم في اليوم أو 0.7 إلى 1.0 ملجم لكل متر مربع من مساحة سطح الجسم في اليوم</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال المصابون بمتلازمة تيرنر:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة 0.045 إلى 0.067 ملجم لكل كلجم من وزن الجسم في اليوم أو 1.3 إلى 2.0 ملجم لكل متر مربع من مساحة سطح الجسم في اليوم</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال المصابون بمرض في الكلى:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة 0.050 ملجم لكل كلجم من وزن الجسم في اليوم أو 1.4 ملجم لكل متر مربع من مساحة سطح الجسم في اليوم</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال المولودون صغارًا بالنسبة لسن الحمل (</strong><strong>SGA</strong><strong>):</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة 0.035 ملجم لكل كلجم من وزن الجسم في اليوم أو 1.0 ملجم لكل متر مربع من مساحة سطح الجسم في اليوم حتى الوصول إلى الطول النهائي. (في التجارب السريرية للأطفال قصار القامة المولودين صغارًا بالنسبة لسن الحمل (SGA)، فقد استُخدمت الجرعتان 0.033 و0.067 ملجم لكل كلجم من وزن الجسم عادةً)</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال المصابون بمتلازمة نونان:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة 0.066 ملجم لكل كلجم من وزن الجسم يوميًا، ومع ذلك فقد يقرر طبيبك أن 0.033 ملجم لكل كلجم من وزن الجسم يوميًا تكفي.</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البالغون الذين يعانون من انخفاض إفراز هرمون النمو أو انعدامه:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا استمر نقص هرمون النمو بعد اكتمال النمو، ينبغي متابعة العلاج. تبلغ الجرعة المبدئية المعتادة 0.2 إلى 0.5 ملجم في اليوم. وسيتم تعديلها حتى تصل إلى الجرعة المناسبة. إذا بدأ نقص هرمون النمو خلال فترة البلوغ، فإن الجرعة المبدئية المعتادة تبلغ 0.1 إلى 0.3 ملجم في اليوم. وسيزيد طبيبك هذه الجرعة كل شهر حتى تصل إلى الجرعة التي تحتاج إليها. تبلغ الجرعة القصوى المعتادة 1.0&nbsp;ملجم في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متى يجب استخدام نورديتروبين فلكس برو</strong></p><p dir="RTL">احقن جرعتك اليومية في الجلد كل ليلة قبل النوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية استخدام نورديتروبين فلكس برو</strong></p><p dir="RTL">يأتي محلول هرمون النمو نورديتروبين فلكس برو في قلم 1.5 مل معبأ مُسبقًا متعدد الجرعات للاستعمال مرة واحدة فقط.</p><p dir="RTL">تتوفر التعليمات الكاملة حول كيفية استخدام قلم نورديتروبين فلكس برو في ظهر الصفحة. وفيما يلي النقاط الأساسية من التعليمات:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحقق من المحلول قبل استعماله بتدوير القلم رأسًا على عقب مرة أو مرتين. لا تستخدم القلم إذا كان المحلول غائمًا أو مشوه اللون (راجع الصفحة 8، الخطوة أ)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلم نورديتروبين فلكس برو مُصمَّم للاستخدام مع إبر نوفوفاين ونوفوتويست أحادية الاستعمال، والتي يصل طولها حتى 8 ملم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدم دائمًا إبرة جديدة لكل عملية حقن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بتغيير منطقة الحقن لتجنب إيذاء جلدك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للتأكد من الحصول على الجرعة الصحيحة وعدم حقن الهواء، تحقق من تدفق هرمون النمو قبل عملية الحقن الأولى من قلم نورديتروبين فلكس بروالجديد. لا تستخدم القلم إذا لم تظهر قطرة محلول هرمون النمو في طرف الإبرة (راجع الصفحتين 10 و11، الخطوات هـ حتى ز)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تشارك قلم نورديتروبين فلكس برو مع أي شخص آخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما المدة التي ستحتاج لتناول العلاج خلالها</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال المصابون بقصور في النمو بسبب متلازمة تيرنر، أو مرض في الكلى، أو ولادتهم صغارًا بالنسبة لسن الحمل أو متلازمة نونان: سيوصيك طبيبك بمتابعة العلاج حتى تتوقف عن النمو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال أو المراهقون الذين يفتقدون هرمون النمو: سيوصيك طبيبك بمتابعة العلاج حتى مرحلة البلوغ</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتوقف عن استخدام نورديتروبين فلكس برو دون مناقشة الأمر مع طبيبك أولاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت جرعة من نورديتروبين فلكس برو أكثر مما ينبغي لك</strong></p><p dir="RTL"><strong>أخبر طبيبك </strong>إذا حقنت كمية مفرطة من مادة سوماتروبين. يمكن أن يتسبب تناول جرعة زائدة على المدى الطويل في نمو غير طبيعي وخشونة في ملامح الوجه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت استخدام نورديتروبين فلكس برو</strong></p><p dir="RTL">تناول الجرعة التالية كالمعتاد في الوقت الطبيعي. <strong>لا تأخذ جرعة مضاعفة‫</strong> لتعويض جرعة فائتة.&rlm;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام نورديتروبين فلكس برو</strong></p><p dir="RTL">لا تتوقف عن استخدام نورديتروبين فلكس برو دون مناقشة الأمر مع طبيبك أولاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى بشأن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي المتابعين لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من أنه لا يُصاب الجميع بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الملحوظة في الأطفال والبالغين </strong>(معدل التكرار غير معروف)</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، الأزيز، تورم الجفون، أو الوجه أو الشفاه، الانهيار الكامل.</strong> قد يكون أيُّ من هذه الآثار علامة على الإصابة بتفاعل تحسسي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الصداع، ومشكلات في الرؤية، والشعور بالإعياء </strong><em>(الغثيان) </em>و<strong>التوعك</strong> <strong>(</strong><em>التقيؤ</em>). قد تكون هذه الآثار علامات على ارتفاع الضغط في الدماغ</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تنخفض مستويات <strong>ثيروكسين مصل الدم</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>فرط سكر الدم</strong> (ارتفاع مستويات السكر في الدم)</p><p dir="RTL">إذا ظهر عليك أي من هذه الآثار، <strong>فعليك زيارة الطبيب في أقرب وقت ممكن.</strong> توقف عن استخدام نورديتروبين فلكس برو حتى يخبرك طبيبك بإمكانية متابعة العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لقد لوحظ وبشكل نادر تشكل أجسام مضادة موجّهة ضد سوماتروبين خلال العلاج باستخدام نورديتروبين.</p><p dir="RTL">لقد تم تسجيل زيادة في مستويات إنزيمات الكبد.</p><p dir="RTL">لقد تم أيضًا الإبلاغ عن حالات من سرطان الدم وانتكاسة في أورام الدماغ لدى المرضى الذين يتلقون علاجًا باستخدام سوماتروبين (المكوّن الفعال في نورديتروبين فلكس برو)، رغم عدم وجود دليل على أن سوماتروبين كان مسؤولا عن ذلك.</p><p dir="RTL">إذا كنت تعتقد أنك تعاني من أي من هذه الأمراض، فتحدّث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية أخرى في الأطفال</strong></p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب حتى طفل واحد من بين 100 طفل)</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الاحمرار،</strong> والحكة والألم في موضع الحقن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تضخم الثدي</strong> (التثدي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة</strong> (قد تصيب حتى طفل واحد من بين 1000 طفل)</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم <strong>العضلات</strong> والمفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تورم اليدين</strong> والقدمين بسبب احتباس السوائل.</p><p dir="RTL">في حالات نادرة، شعر الأطفال الذين يستخدمون نورديتروبين فلكس برو بألم في الورك أو الركبة أو بدأوا في العرج. قد تسبب هذه الأعراض مرض يؤثر على الجزء العلوي من عظمة الفخذ (<em>مرض ليغ-كالفيه</em>) أو بسبب انزلاق طرف العظمة من الغضروف (<em>انزلاق مُشاش رأس الفخذ</em>)، وقد لا تكون بسبب استخدام نورديتروبين فلكس برو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في الأطفال المصابين <strong>بمتلازمة تيرنر، </strong>لوحظت بضع حالات من <strong>زيادة نمو اليدين والقدمين</strong> مقارنة بالطول في التجارب السريرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لقد أظهرت تجربة سريرية في الأطفال المصابين بمتلازمة تيرنر أن تناول جرعات عالية من نورديتروبين يمكن أن يؤدي إلى زيادة مخاطر الإصابة بالتهابات الأذن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تفاقمت أي من هذه الآثار الجانبية،</strong> أو إذا لاحظت ظهور أي آثار جانبية غير مذكورة في هذه النشرة، يُرجى إخبار طبيبك أو الصيدلي حيث إنه قد تكون هناك حاجة إلى تقليل الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية أخرى في البالغين</strong></p><p dir="RTL"><strong>شائعة جدًا</strong> (قد تصيب أكثر من بالغ واحد من بين 10 بالغين):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تورم اليدين</strong> والقدمين بسبب احتباس السوائل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب حتى بالغ واحد من بين 10 بالغين):</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور <strong>بتنمل الجلد </strong>(<em>التنمل</em>) والخدر أو ألم في الأصابع بصفة أساسية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ألم المفاصل</strong> والتصلب؛ ألم في العضلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب حتى بالغ واحد من بين 100 بالغ)</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري من النوع الثاني</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>متلازمة نفق الرسغ؛</strong> أي الشعور بالنخز وألم في الأصابع واليدين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الحكة</strong> (يمكن أن تكون حادة) والشعور بالألم في منطقة الحقن</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تصلب العضلات</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تضخم الثدي</strong> (التثدي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أُصبت بأي أثر جانبي، فتحدث إلى طبيبك أو الصيدلي. يشمل هذا أي آثار جانبية محتملة غير واردة في هذه النشرة</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى الإبلاغ عن الأعراض الجانبية إلى:</p><table border="1" cellspacing="1" cellpadding="1" dir="ltr" style="width:500px"><tbody><tr><td><p>:المركز الوطني للتيقظ والسلامة الدوائية</p><p>للاتصال بالمركز الموحد للهيئة العامة للغذاء والدواء: 19999</p><p>npc.drug@sfda.gov.sa :بريد الالكتروني</p><p>https://ade.sfda.gov.sa :الموقع الالكتروني</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد كلمة &quot;EXP/&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قم بتخزين</strong> أقلام نورديتروبين فلكس برو <strong>غير المستعملة</strong> في ثلاجة (تتراوح درجة حرارتها من 2-8 درجات مئوية) في العبوة الكرتونية الخارجية لحمايتها من الضوء. ولا تعرّضها للتجمد أو الحرارة. لا تُحفَظ بالقرب من أي من عناصر التبريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>عند استخدام</strong> نورديتروبين فلكس برو 10 ملجم/1.5 مل، يمكنك <strong>إما:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حفظه حتى 4 أسابيع في ثلاجة (تتراوح درجة حرارتها ما بين 2-8 درجات مئوية)، <strong>أو</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حفظه حتى 3 أسابيع في درجة حرارة الغرفة (أقل من 25 درجة مئوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستمر في استخدام أقلام نورديتروبين فلكس برو إذا كانت قد تجمدت أو تعرّضت لدرجات حرارة مفرطة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم أقلام نورديتروبين فلكس برو إذا كان محلول هرمون النمو غائمًا أو مشوه اللون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احرص دومًا على تخزين نورديتروبين فلكس برو دون إرفاق إبرة.</p><p dir="RTL">حافظ دومًا على غطاء القلم مغلقًا بشكل كامل على نورديتروبين فلكس برو في حالة عدم استخدامه.</p><p dir="RTL">استخدم دائمًا إبرة جديدة لكل عملية حقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي المتابع لك عن كيفية التخلّص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات نورديتروبين فلكس برو</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتمثل المادة الفعالة في سوماتروبين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتمثل مواد السواغ في: مانيتول، وهيستيدين، وبولوكسامير 188، وفينول، وماء للحقن، وحمض الهيدروكلوريك وهيدروكسيد الصوديوم.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما شكل نورديتروبين فلكس برو ومحتويات العبوة</strong></p><p dir="RTL">نورديتروبين فلكس برو عبارة عن محلول صافٍ وعديم اللون للحقن يأتي في قلم 1.5 مل مُعبأ مُسبقًا متعدد الجرعات للاستعمال مرة واحدة فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي 1 مل من المحلول على 6.7 ملجم من مادة سوماتروبين.</p><p dir="RTL">يعادل 1 ملجم من مادة سوماتروبين 3 وحدات دولية من سوماتروبين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر نورديتروبين فلكس برو بثلاثة تراكيز:</p><p dir="RTL">5 ملجم/1.5 مل و10 ملجم/1.5 مل و15 ملجم/1.5 مل (أي ما يعادل 3.3 ملجم/مل و6.7 ملجم/مل و10 ملجم/مل على التوالي) في عبوات بأحجام مكونة من 1 أو 5 أقلام مملوءة مسبقًا. قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق:</strong></p><p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Novo All&eacute;</p><p dir="RTL">DK-2880 Bagsv&aelig;rd, Denmark</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة الصانعة:</strong></p><p dir="RTL">Novo Nordisk A/S</p><p dir="RTL">Hallas All&eacute;</p><p dir="RTL">DK-4400 Kalundborg, Denmark</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	11/2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Norditropin FlexPro 5 mg/1.5 mL, solution for injection in pre-filled pen
Norditropin FlexPro 10 mg/1.5 mL, solution for injection in pre-filled pen
Norditropin FlexPro 15 mg/1.5 mL, solution for injection in pre-filled pen
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Norditropin FlexPro: 5 mg/1.5 mL
One mL of solution contains 3.3 mg somatropin

Norditropin FlexPro: 10 mg/1.5 mL
One mL of solution contains 6.7 mg somatropin

Norditropin FlexPro: 15 mg/1.5 mL
One mL of solution contains 10 mg somatropin

somatropin (recombinant DNA origin produced in E-coli)

1 mg of somatropin corresponds to 3 IU (International Unit) of somatropin

For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection in pre-filled pen

Clear, colourless solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Children: </u></p><p>Growth failure due to growth hormone deficiency (GHD)</p><p>&nbsp;</p><p>Growth failure in girls due to gonadal dysgenesis (Turner syndrome)</p><p>&nbsp;</p><p>Growth retardation in prepubertal children due to chronic renal disease</p><p>&nbsp;</p><p>Growth disturbance (current height SDS &lt;&nbsp;-2.5 and parental adjusted height SDS &lt;&nbsp;-1) in short children born small for gestational age (SGA), with a birth weight and/or length below -2&nbsp;SD, who failed to show catch-up growth (HV SDS &lt;&nbsp;0 during the last year) by 4&nbsp;years of age or later.</p><p>&nbsp;</p><p>Growth failure due to Noonan syndrome.</p><p>&nbsp;</p><p><u>Adults:</u></p><p><u>Childhood onset growth hormone deficiency:</u></p><p>Patients with childhood onset GHD should be re-evaluated for growth hormone secretory capacity after growth completion. Testing is not required for those with more than three pituitary hormone deficits, with severe GHD due to a defined genetic cause, due to structural hypothalamic pituitary abnormalities, due to central nervous system tumours or due to high-dose cranial irradiation, or with GHD secondary to a pituitary/hypothalamic disease or insult, if measurements of serum insulin-like growth factor 1 (IGF-1) is &lt; -2 SDS after at least four weeks off growth hormone treatment.</p><p>In all other patients an IGF-1 measurement and one growth hormone stimulation test is required.</p><p>&nbsp;</p><p><u>Adult onset growth hormone deficiency: </u></p><p>Pronounced GHD in known hypothalamic-pituitary disease, cranial irradiation and traumatic brain injury. GHD should be associated with one other deficient axis, other than prolactin. GHD should be demonstrated by one provocative test after institution of adequate replacement therapy for any other deficient axis.</p><p>&nbsp;</p><p>In adults, the insulin tolerance test is the provocative test of choice. When the insulin tolerance test is contraindicated, alternative provocative tests must be used. The combined arginine-growth hormone releasing hormone is recommended. An arginine or glucagon test may also be considered; however, these tests have less established diagnostic value than the insulin tolerance test.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Norditropin should only be prescribed by doctors with special knowledge of the therapeutic indication of use.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The dosage is individual and must always be adjusted in accordance with the individual&#39;s clinical and biochemical response to therapy.</p><p><strong>&nbsp;</strong></p><p><em><u>Generally recommended dosages:</u></em></p><p><strong>&nbsp;</strong></p><p><em>Paediatric population</em>:</p><p><u>Growth hormone insufficiency</u></p><p>0.025‑0.035&nbsp;mg/kg/day or 0.7‑1.0&nbsp;mg/m<sup>2</sup>/day</p><p>When GHD persists after growth completion, growth hormone treatment should be continued to achieve full somatic adult development including lean body mass and bone mineral accrual (for guidance on dosing, see Replacement therapy in adults).</p><p>&nbsp;</p><p><u>Turner syndrome</u></p><p>0.045‑0.067&nbsp;mg/kg/day or 1.3‑2.0&nbsp;mg/m<sup>2</sup>/day</p><p>&nbsp;</p><p><u>Chronic renal disease</u></p><p>0.050&nbsp;mg/kg/day or 1.4&nbsp;mg/m<sup>2</sup>/day (see section 4.4)</p><p><u>&nbsp;</u></p><p><u>Small for Gestational Age</u></p><p>0.035&nbsp;mg/kg/day or 1.0&nbsp;mg/m<sup>2</sup>/day</p><p>&nbsp;</p><p>A dose of 0.035&nbsp;mg/kg/day is usually recommended until final height is reached (see section 5.1).</p><p>Treatment should be discontinued after the first year of treatment, if the height velocity SDS is below +1.</p><p>Treatment should be discontinued if height velocity is &lt;&nbsp;2&nbsp;cm/year and, if confirmation is required, bone age is &gt;&nbsp;14&nbsp;years (girls) or &gt;&nbsp;16&nbsp;years (boys), corresponding to closure of the epiphyseal growth plates.</p><p><u>&nbsp;</u></p><p><u>Noonan syndrome:</u></p><p>0.066&nbsp;mg/kg/day is the recommended dose, however in some cases 0.033 mg/kg/day may be sufficient (see section 5.1).</p><p>Treatment should be discontinued at the time of epiphyseal closure (see section 4.4).</p><p>&nbsp;</p><p><em>Adult population:</em></p><p><u>Replacement therapy in adults</u></p><p>The dosage must be adjusted to the need of the individual patient.</p><p>In patients with childhood onset GHD, the recommended dose to restart is 0.2‑0.5&nbsp;mg/day with subsequent dose adjustment on the basis of IGF-1 concentration determination.</p><p>In patients with adult onset GHD, it is recommended to start treatment with a low dose: 0.1‑0.3&nbsp;mg/day. It is recommended to increase the dosage gradually at monthly intervals based on the clinical response and the patient&rsquo;s experience of adverse events. Serum IGF-1 can be used as guidance for the dose titration. Women may require higher doses than men, with men showing an increasing IGF-1 sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement are undertreated while men are overtreated.</p><p>Dose requirements decline with age. Maintenance dosages vary considerably from person to person, but seldom exceed 1.0&nbsp;mg/day.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Generally, daily subcutaneous administration in the evening is recommended. The injection site should be varied to prevent lipoatrophy.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Somatropin must not be used when there is any evidence of activity of a tumour. Intracranial tumours must be inactive and antitumour therapy must be completed prior to starting growth hormone (GH) therapy. Treatment should be discontinued if there is evidence of tumour growth.

Somatropin should not be used for longitudinal growth promotion in children with closed epiphyses.

Patients with acute critical illness suffering complications following open heart surgery, abdominal surgery, multiple accidental trauma, acute respiratory failure, or similar conditions should not be treated with somatropin (see section 4.4).

In children with chronic renal disease, treatment with Norditropin FlexPro should be discontinued at renal transplantation.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p>Children treated with somatropin should be regularly assessed by a specialist in child growth. Somatropin treatment should always be instigated by a physician with special knowledge of growth hormone insufficiency and its treatment. This is true also for the management of Turner syndrome, chronic renal disease, SGA and Noonan syndrome. Data of final adult height following the use of Norditropin are limited for children with Noonan Syndrome and are not available for children with chronic renal disease.</p><p>&nbsp;</p><p>The maximum recommended daily dose should not be exceeded (see section 4.2).</p><p>&nbsp;</p><p>The stimulation of longitudinal growth in children can only be expected until epiphyseal closure.</p><p>&nbsp;</p><p><em><u>Children</u></em></p><p><u>Treatment of growth hormone deficiency in patients with Prader-Willi syndrome</u></p><p>There have been reports of sudden death after initiating somatropin therapy in patients with Prader-Willi syndrome, who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnoea, or unidentified respiratory infection.</p><p>&nbsp;</p><p><u>Small for Gestational Age</u></p><p>In short children born SGA other medical reasons or treatments that could explain growth disturbance should be ruled out before starting treatment.</p><p>&nbsp;</p><p>Experience in initiating treatment in SGA patients near onset of puberty is limited. It is therefore not recommended to initiate treatment near onset of puberty.</p><p>Experience with patients with Silver-Russell syndrome is limited.</p><p>&nbsp;</p><p><u>Turner syndrome</u></p><p>Monitoring of growth of hands and feet in Turner syndrome patients treated with somatropin is recommended, and a dose reduction to the lower part of the dose range should be considered if increased growth is observed.</p><p>&nbsp;</p><p>Girls with Turner syndrome generally have an increased risk of otitis media, which is why otological evaluation is recommended on at least an annual basis.</p><p>&nbsp;</p><p><u>Chronic renal disease</u></p><p>The dosage in children with chronic renal disease is individual and must be adjusted according to the individual response to therapy (see section 4.2). The growth disturbance should be clearly established before somatropin treatment by following growth on optimal treatment for renal disease over one year. Conservative management of uraemia with customary medicinal product and if needed dialysis should be maintained during somatropin therapy.</p><p>&nbsp;</p><p>Patients with chronic renal disease normally experience a decline in renal function as part of the natural course of their illness. However, as a precautionary measure during somatropin treatment, renal function should be monitored for an excessive decline or increase in the glomerular filtration rate (which could imply hyperfiltration).</p><p><u>&nbsp;</u></p><p><u>Scoliosis</u></p><p>Scoliosis is known to be more frequent in some of the patient groups treated with somatropin for example Turner syndrome and Noonan syndrome. In addition, rapid growth in any child can cause progression of scoliosis. Somatropin has not been shown to increase the incidence or severity of scoliosis. Signs of scoliosis should be monitored during treatment.</p><p><u>&nbsp;</u></p><p><u>Blood glucose and insulin</u></p><p>In Turner syndrome and SGA children it is recommended to measure fasting insulin and blood glucose before start of treatment and annually thereafter. In patients with increased risk of diabetes mellitus (e.g. familial history of diabetes, obesity, severe insulin resistance, acanthosis nigricans), oral glucose tolerance testing (OGTT) should be performed. If overt diabetes occurs, somatropin should not be administered.</p><p>&nbsp;</p><p>Somatropin has been found to influence carbohydrate metabolism, therefore, patients should be observed for evidence of glucose intolerance.</p><p>&nbsp;</p><p><u>IGF-1</u></p><p>In Turner syndrome and SGA children it is recommended to measure the IGF-1 level before start of treatment and twice a year thereafter. If on repeated measurements IGF-1 levels exceed +2&nbsp;SD compared to references for age and pubertal status, the dose should be reduced to achieve an IGF-1 level within the normal range.</p><p>Some of the height gain obtained with treating short children born SGA with somatropin may be lost if treatment is stopped before final height is reached.</p><p>&nbsp;</p><p><em><u>Adults</u></em></p><p><u>Growth hormone deficiency in adults</u></p><p>Growth hormone deficiency in adults is a lifelong disease and needs to be treated accordingly, however, experience in patients older than 60&nbsp;years and in patients with more than five years of treatment in adult growth hormone deficiency is still limited.</p><p>&nbsp;</p><p><em><u>Adults and Children</u></em></p><p><u>Pancreatitis</u></p><p>Although rare, pancreatitis should be considered in somatropin-treated patients who develop abdominal pain, especially in children.</p><p><em><u>&nbsp;</u></em></p><p><em><u>General</u></em></p><p><u>Neoplasms </u></p><p>There is no evidence for increased risk of new primary cancers in children or in adults treated with somatropin.</p><p>&nbsp;</p><p>In patients in complete remission from tumours or malignant disease, somatropin therapy has not been associated with an increased relapse rate.</p><p>&nbsp;</p><p>An overall slight increase in second neoplasms has been observed in childhood cancer survivors treated with growth hormone, with the most frequent being intracranial tumours. The dominant risk factor for second neoplasms seems to be prior exposure to radiation.</p><p>&nbsp;</p><p>Patients who have achieved complete remission of malignant disease should be followed closely for relapse after commencement of somatropin therapy.</p><p>&nbsp;</p><p><u>Leukaemia</u></p><p>Leukaemia has been reported in a small number of growth hormone deficient patients, some of whom have been treated with somatropin. However, there is no evidence that leukaemia incidence is increased in somatropin recipients without predisposition factors.</p><p>&nbsp;</p><p><u>Benign intracranial hypertension</u></p><p>In the event of severe or recurrent headache, visual problems, nausea, and/or vomiting, a funduscopy for papilloedema is recommended. If papilloedema is confirmed, a diagnosis of benign intracranial hypertension should be considered and if appropriate the somatropin treatment should be discontinued.</p><p>&nbsp;</p><p>At present there is insufficient evidence to guide clinical decision making in patients with resolved intracranial hypertension. If somatropin treatment is restarted, careful monitoring for symptoms of intracranial hypertension is necessary.</p><p>&nbsp;</p><p>Patients with growth hormone deficiency secondary to an intracranial lesion should be examined frequently for progression or recurrence of the underlying disease process.</p><p>&nbsp;</p><p><u>Thyroid function</u></p><p>Somatropin increases the extrathyroidal conversion of T4 to T3 and may, as such, unmask incipient hypothyroidism. Monitoring of thyroid function should therefore be conducted in all patients. In patients with hypopituitarism, standard replacement therapy must be closely monitored when somatropin therapy is administered.</p><p>&nbsp;</p><p>In patients with a pituitary disease in progression, hypothyroidism may develop.</p><p>Patients with Turner syndrome have an increased risk of developing primary hypothyroidism associated with anti-thyroid antibodies. As hypothyroidism interferes with the response to somatropin therapy patients should have their thyroid function tested regularly and should receive replacement therapy with thyroid hormone when indicated.</p><p>&nbsp;</p><p><u>Insulin sensitivity</u></p><p>Because somatropin may reduce insulin sensitivity, patients should be monitored for evidence of glucose intolerance (see section 4.5). For patients with diabetes mellitus, the insulin dose may require adjustment after somatropin containing product therapy is instituted. Patients with diabetes or glucose intolerance should be monitored closely during somatropin therapy.</p><p>&nbsp;</p><p><u>Antibodies</u></p><p>As with all somatropin containing products, a small percentage of patients may develop antibodies to somatropin. The binding capacity of these antibodies is low, and there is no effect on growth rate. Testing for antibodies to somatropin should be carried out in any patient who fails to respond to therapy.</p><p><u>&nbsp;</u></p><p><u>Acute adrenal insufficiency</u></p><p>Introduction of somatropin treatment may result in inhibition of 11&beta;HSD-1 and reduced serum cortisol concentrations. In patients treated with somatropin, previously undiagnosed central (secondary) hypoadrenalism may be unmasked and glucocorticoid replacement may be required. In addition, patients treated with glucocorticoid replacement therapy for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses, following initiation of somatropin treatment (see section 4.5).</p><p>&nbsp;</p><p><u>Use with oral oestrogen therapy</u></p><p>If a woman taking somatropin begins oral oestrogen therapy, the dose of somatropin may need to be increased to maintain the serum IGF-1 levels within the normal age-appropriate range. Conversely, if a woman on somatropin discontinues oral oestrogen therapy, the dose of somatropin may need to be reduced to avoid excess of growth hormone and/or side effects (see section 4.5).</p><p>&nbsp;</p><p><u>Slipped capital femoral epiphysis</u></p><p>In patients with endocrine disorders, including growth hormone deficiency, slipped epiphyses of the hip may occur more frequently than in the general population. A patient treated with somatropin who develops a limp or complains of hip or knee pain should be evaluated by a physician.</p><p>&nbsp;</p><p><em><u>Clinical trial experience</u></em></p><p>Two placebo-controlled clinical trials of patients in intensive care units have demonstrated an increased mortality among patients suffering from acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure, who were treated with somatropin in high doses (5.3‑8&nbsp;mg/day). The safety of continuing somatropin treatment in patients receiving replacement doses for approved indications who concurrently develop these illnesses has not been established. Therefore, the potential benefit of treatment continuation with somatropin in patients having acute critical illnesses should be weighed against the potential risk.</p><p>&nbsp;</p><p>One open-label, randomised clinical trial (dose range 0.045‑0.090&nbsp;mg/kg/day) with patients with Turner syndrome indicated a tendency for a dose-dependent risk of otitis externa and otitis media. The increase in ear infections did not result in more ear operations/tube insertions compared to the lower dose group in the trial.</p><p>&nbsp;</p><p><u>Excipients</u></p><p>Norditropin contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per 1.5 mL, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant treatment with glucocorticoids inhibits the growth-promoting effect of Norditropin. Patients with ACTH deficiency should have their glucocorticoid replacement therapy carefully adjusted to avoid any inhibitory effect on growth.</p><p>Growth hormone decreases the conversion of cortisone to cortisol and may unmask previously undiscovered central hypoadrenalism or render low glucocorticoid replacement doses ineffective (see section 4.4).</p><p>&nbsp;</p><p>In women on oral oestrogen replacement, a higher dose of growth hormone may be required to achieve the treatment goal (see section 4.4).</p><p>&nbsp;</p><p>Data from an interaction study performed in growth hormone deficient adults suggest that somatropin administration may increase the clearance of compounds known to be metabolised by cytochrome P450 isoenzymes. The clearance of compounds metabolised by cytochrome P450 3A4 (e.g. sex steroids, corticosteroids, anticonvulsants and cyclosporine) may be especially increased resulting in lower plasma levels of these compounds. The clinical significance of this is unknown.</p><p>&nbsp;</p><p>The effect of somatropin on final height can also be influenced by additional therapy with other hormones, e.g. gonadotropin, anabolic steroids, oestrogen and thyroid hormone.</p><p>&nbsp;</p><p>In insulin treated patients adjustment of insulin dose may be needed after initiation of somatropin treatment (see section 4.4).</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>Animal studies are insufficient with regard to effects on pregnancy, embryo-foetal development, parturition or postnatal development. No clinical data on exposed pregnancies are available.</p><p>Therefore, somatropin containing products are not recommended during pregnancy and in women of childbearing potential not using contraception.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>There have been no clinical studies conducted with somatropin containing products in breast-feeding women. It is not known whether somatropin is excreted in human milk. Therefore caution should be exercised when somatropin containing products are administered to breast-feeding women.</p><p>&nbsp;</p><p><u>Fertility</u></p><p><strong><u>&nbsp;</u></strong></p><p>Fertility studies with Norditropin have not been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Norditropin FlexPro has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Growth hormone deficient patients are characterised by extracellular volume deficit. When treatment with somatropin is initiated, this deficit is corrected. Fluid retention with peripheral oedema may occur especially in adults. Carpal tunnel syndrome is uncommon, but may be seen in adults. The symptoms are usually transient, dose dependent and may require transient dose reduction.</p><p>Mild arthralgia, muscle pain and paresthesia may also occur but are usually self-limiting.</p><p>&nbsp;</p><p>Adverse reactions in children are uncommon or rare.</p><p>&nbsp;</p><p>Clinical trial experience:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>System organ classes</p></td><td><p>Very common</p><p>(&ge;&nbsp;1/10)</p></td><td><p>Common</p><p>(&ge;&nbsp;1/100 to &lt;&nbsp;1/10)</p></td><td><p>Uncommon</p><p>(&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100)</p></td><td><p>Rare</p><p>(&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000)</p></td></tr><tr><td><p><em><u>Metabolism and nutrition disorders</u></em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>In adults Diabetes mellitus type 2</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><em><u>Nervous system disorders</u></em></p></td><td><p>&nbsp;</p></td><td><p>In adults headache and paraesthesia</p></td><td><p>In adults carpal tunnel syndrome. In children headache</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><em><u>Skin and subcutaneous tissue disorders</u></em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;In adults pruritus</p></td><td><p>In children rash</p></td></tr><tr><td><p><em><u>Musculoskeletal, connective tissue disorders</u></em></p></td><td><p>&nbsp;</p></td><td><p>In adults arthralgia, joint stiffness and myalgia</p></td><td><p>In adults muscle stiffness</p></td><td><p>In children arthralgia and myalgia</p></td></tr><tr><td><p><em><u>Reproductive system and breast disorders </u></em></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>In adults and children Gynaecomastia</p></td><td><p>&nbsp;</p></td></tr><tr><td><p><em><u>General disorders and administration site conditions</u></em></p></td><td><p>In adults peripheral oedema (see text above)</p></td><td><p>&nbsp;</p></td><td><p>In adults and children injection site pain. In children injection site reaction</p></td><td><p>In children peripheral oedema</p></td></tr></tbody></table><p>&nbsp;</p><p>In children with Turner syndrome increased growth of hands and feet has been reported during somatropin therapy.</p><p>&nbsp;</p><p>A tendency for increased incidence of otitis media in Turner syndrome patients treated with high doses of Norditropin has been observed in one open-label randomised clinical trial. However, the increase in ear infections did not result in more ear operations/tube insertions compared to the lower dose group in the trial.</p><p>&nbsp;</p><p><u>Post-marketing experience:</u></p><p>&nbsp;</p><p>In addition to the above mentioned adverse drug reactions, those presented below have been spontaneously reported and are by an overall judgement considered possibly related to Norditropin treatment. Frequencies of these adverse events cannot be estimated from the available data:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Neoplasms benign and malignant (including cysts and polyps): Leukaemia has been reported in a small number of growth hormone deficiency patients (see section 4.4)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Immune system disorders: Hypersensitivity (see section 4.3). Formation of antibodies directed against somatropin. The titres and binding capacities of these antibodies have been very low and have not interfered with the growth response to Norditropin administration</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Endocrine disorders: Hypothyroidism. Decrease in serum thyroxin levels (see section 4.4)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Metabolism and nutrition disorders: Hyperglycaemia (see section 4.4)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Nervous system disorders: Benign intracranial hypertension (see section 4.4)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Musculoskeletal and connective tissue disorders: Legg-Calv&eacute;-Perthes disease. Legg-Calv&eacute;-Perthes disease may occur more frequently in patients with short stature</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Investigations: Increase in blood alkaline phosphatase level.</p><p><u>&nbsp;</u></p><p><u>Please report adverse drug events to:</u><u> </u></p><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Acute overdosage can lead to low blood glucose levels initially, followed by high blood glucose levels. These decreased glucose levels have been detected biochemically, but without clinical signs of hypoglycaemia. Long-term overdosage could result in signs and symptoms consistent with the known effects of human growth hormone excess.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Somatropin and somatropin agonists. ATC: H01AC01.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Norditropin FlexPro contains somatropin, which is human growth hormone produced by recombinant DNA-technology. It is an anabolic peptide of 191 amino acids stabilised by two disulphide bridges with a molecular weight of approximately 22,000&nbsp;Daltons.</p><p>&nbsp;</p><p>The major effects of somatropin are stimulation of skeletal and somatic growth and pronounced influence on the body&rsquo;s metabolic processes.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>When growth hormone deficiency is treated a normalisation of body composition takes place resulting in an increase in lean body mass and a decrease in fat mass.</p><p>Somatropin exerts most of its actions through insulin-like growth factor 1 (IGF-1), which is produced in tissues throughout the body but predominantly by the liver.</p><p>More than 90% of IGF-1 is bound to binding proteins (IGFBPs) of which IGFBP-3 is the most important.</p><p>&nbsp;</p><p>A lipolytic and protein sparing effect of the hormone becomes of particular importance during stress.</p><p>&nbsp;</p><p>Somatropin also increases bone turnover indicated by an increase in plasma levels of biochemical bone markers. In adults bone mass is slightly decreased during the initial months of treatment due to more pronounced bone resorption, however, bone mass increases with prolonged treatment.</p><p><u>&nbsp;</u></p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p>In clinical trials in short children born SGA doses of 0.033 and 0.067&nbsp;mg/kg/day have been used for treatment until final height. In 56&nbsp;patients who were continuously treated and have reached (near) final height, the mean change from height at start of treatment was +1.90&nbsp;SDS (0.033&nbsp;mg/kg/day) and +2.19&nbsp;SDS (0.067&nbsp;mg/kg/day). Literature data from untreated SGA children without early spontaneous catch-up suggest a late growth of 0.5&nbsp;SDS. Long-term safety data are still limited.</p><p>&nbsp;</p><p>A growth promoting effect was observed following 104 weeks (primary endpoint) and 208 weeks treatment with once-daily dosing of Norditropin 0.033&nbsp;mg/kg/day and 0.066&nbsp;mg/kg/day in 51 children aged 3 to &lt;11 years with short stature due to Noonan syndrome.</p><p>&nbsp;</p><p>A statistically significant increase from baseline in mean height SDS at 104 weeks (primary endpoint) was observed with 0.033 mg/kg/day (0.84 SDS) and 0.066 mg/kg/day (1.47 SDS). A mean difference of 0.63 SDS [95 % CI: 0.38; 0.88] was observed between the groups at 104 weeks; the difference was greater after 208 weeks with an mean difference of 0.99 SDS [95 % CI: 0.62; 1.36] (figure 1).</p><p><img alt="" width="643" height="332" src="data:image/png;base64,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" /></p><p><strong>Figure </strong><!--[if supportFields]><b><span lang=DA
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span></span></b><b><span
style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US'><span
style='mso-spacerun:yes'> </span>SEQ Figure \* ARABIC </span></b><b><span
lang=DA style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-separator'></span></span></b><![endif]--><strong>1</strong><!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-GB'><span
style='mso-element:field-end'></span></span><![endif]--><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Height SDS (national) change from baseline to week 208</strong></p><p>&nbsp;</p><p>The mean height velocity and height velocity SDS increased markedly from baseline during the first year of treatment with a greater increase with 0.066&nbsp;mg/kg/day than with 0.033&nbsp;mg/kg/day. The mean height velocity SDS was maintained above 0 in both groups after a two-year treatment and also after four years of treatment in the 0.066 mg/kg/day group. The height velocity SDS was greater with 0.066 mg/kg/day than with 0.033 mg/kg/day throughout the trial period (figure 2).</p><p><img alt="" width="609" height="377" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAmEAAAF5CAYAAADXmP0gAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAFXNSURBVHhe7Z0HtN3Enca9Z7PZbHJOCrChd0LHsGDahdBiegmEGgyElguEADHNlNB7Qrmw9B7AxjYGg4Eb00IHO8bGGJviZ8D2Ag7N9G48q280ozvSHd1333tX0kj6fu/8z7sajUajMjOfZv4a9RMRhgwZ0mSEEOIirK8IIXnBVl9RhBFCcgvrK0JIXrDVVxRhhJDcwvqKEJIXbPUVRRghJLewviKE5AVbfdUkwgghhBBCSPI0ibD//d//Vb8IIYQQQkgSQG9RhBFCCCGEpIxVhBFCCCGEkOShCCOEEEIIyQAORxJCCCGEpAx9wgghhBBCMoA+YYQQQgghGUERRgghhBCSARyOJIQQQghJGfqEEUIIIYRkAH3CCCGEEEIygiKsj3z88cfikEMOEYMGDRIHHHAAjUYriO2///5i3333FQceeKCYMWOGOP3008Wee+5pjUuj0fJtv/nNb8TkyZNVy54eHI7sI7NmzRLbb7+9GD9+vHjppZfEtGnTaDRaQWzq1KnyAWvs2LFin332EY899hjLOY1WMEOZRjkfPXq0atnTgT5hHQAibL/99hPffPONCiGEFIljjz1W/P3vfxd/+MMfxCeffKJCCSFF4qSTThL33HOPWkoH+oR1AIgwPCFnWjnXq6Jfv37KqqLu/dVqXWqlC9RFVeWvEspXI7xfpSZ6l+MuUatUhJ8s0tO/O0kv0+2qiYo8vphtW6zvqlX882Kss4UlQVe9Lrpk3nAv9Qy5rfrtY16ffDJ48GApwg499FDxzjvvqFBHYNlX91ZSZR/0Iu3uyj5oGQfH5p+faqgQxoV3hs6WfZCf8j9kyBAxZswYtZQeFGF9JGsR5jfMZoFRlVsSJbSPaBHRVKnUep/XejW+ouuqVTMs/JEGoqmhabHeqwSrKuPynOGE2cISAdejpir6nlbEzdey1fXJC66KMJb9vJZ90CpO3HVM+vp2tuyDPJV/Z0QYhyN7RrYizC+UzWXSC3eyIvYKeFPD0beKOFyZhalXMyz86KEwrgEqo9Al6W69xosX7kHwsIV1Ck/s+ZcD91YPK+JgW5P465MX3BRhLPut7i2nyz5oEQe/beU7LrxjdLzsg/yU/yxEGH3COkCmIgwFuWVh8QuTX/n5BUE/kcL8Au1X5jodFPTGk4sqjHI/5jYaFDA/vMksDQEq4mAfwfpwRdycP9B8HP6x6/2Z+W1eX623cx5A3PEa6Uoi8SxPukjfPFc9XfaxNVK2MAOvMqx4+anr40PemvIZvW6Ne0hfo+AYZZiRVlvbesRen+h2ljAcQyhOtjgpwuT57e78+NfQhfKfXdnX6zpV/iNxelH2QWwcee9XPSHt7z84V3HhJq6UfRB7jcxto8seGZZ9Z0QY6RlZijBZQCKVQFBoDAsKuyqkcknd7GYl5d/0KGgoNEaBC1UElqe6NgkXcp0voyK25q+Rj9BxhAqtX8jNBqSrq950HK3PQ/zxyrCgIonGw7HodQ1iK1lFd8vmvkP5joaFiB6rquRkPrFOnRvcI5EwTd0TrOpX456oe0+5QRba2Fbms/n6NI4xsq06Ln3aQbbDSWFcFGHyOrQq+1XvmrV132Mh+fKfTdmXkdo8D/HHK8Nk2tE4vSv7IC6OvIZV7/hkFvxzhV3FhTeIHqcfJ1pW/XTCYZqOlH0Qc430MYa2D84/IvtkVfbpE5ZTMhdhQeVpgBtbVjJGYZLB4YKPiqtRYHU8s4CFtwfhNBBXVUpRC9cQktDTUlA4vTRURdxe/mx50PmN+92b8+DjxzUrdRB3vhpE99HTZQ3CrY1tJKxBXN7wW1V2eEq1VqamUzfS8fKE62teyza2DR9LNJ6fD9wjZrLhY/L2ba7MGGdFWORelQRlH4Tv5/B1waVMr/xnV/ZBb86Djx/XLP9x56pBNP3oMoiLEw3XeYsLDxOXN/xOp+yDcF6jcf284B7RSSO+C2WfPmE5JdPhSPUU0VQYW4gws1A1Cktc4Q1vD6KVQU+Idln7ha8qqkZF3H3+onkw8xv3uzfnwcdfZ1bCIO58GQQVlg8qzVDd0t36AG9fTYLLFqaJyxt+6334v5saS+Op10/H29Z7Kg0Lvu63jb0+OGbd+AZ50TTCXOoFA04OR3Zb9oF5L2BVduU/u7IPenMefPx1PRNhbZXtuDiR8CBvceEh4vKG3+mUfRDOm5GP2PLfWM6y7NMnLKdk65jv3/DmU4UkRoTJcFkI5EKjcITi4TcKGpZVYQwKRXS5Z0QrYoDKJyjQbeXPQxZms7LR+TW3abF9y/3o30Avm3GAmV50ncYIDzWMmu7WK7xjbapsbWEBcXnD70ZFb9u+7l2fRmgjHVyjIH4728ZcH/iz+JfayIuJ3M6LG3cuMsJNx3zcNq3KPjDvBY+2yhd+d778Z1f2QSSNlvuKbofluPxE96MxwmPLdlwcMw9xeYvbb1ze8Dulsg96U/4dKPv0CcspWYswib6BA/MLn6zkIje2rrhhZiEI4nrbVkIFX4f76yxlsC3M9MNpePswMmLLn+04Guk14gbbqnjRON2fB/vxxqbrbRhdF0JW9o10GmFq2bbew8ybbqRsYTbMvJnnLeSsG+zXN79i9SpG1SsBzHS8BRXXq1jb2BZEz73McpAO7jH81xV1A2zX4vAywVURJokp+/4qFdbtfW9er86XfzPt8PbJl32ss6VhPw/dl/+aTsvbKLrPEN2V/WA5EgcY17SRN4+4cEVwnN5K85jTLvsgSEOZzG835R/b2I4rLegTllOcEGGJgUqpuaEsLiU53sjwQdOTbCv6sm23eBV6tZPpdYY//elP7oqwRGH5Lxws+7HQJyynUIQViTIcr1fZhYYywk61renLtm3gPSln+SQch+4JO+ywwyjCCk3Rj5dlvxX0CcspM2fOlN+OJIQUk+OOO06+go9vR3711VcqlBBSJE499VRx9913q6V0oE9YB3jrrbfEZpttJs4991x5Qi+77DIajVYAQ3m+9NJLxdZbby0ef/xxseeee4rTTz+d5ZxGK5hdeeWVYpNNNhH333+/atnTgyKsj8ybN0/cd9994uqrrxbXXXcdjUYrkF1zzTVi1KhR4uOPPxZPPPEEyzmNVkC79tprxa233iree+891bKnB4cj+8js2bPF2WefLc444wxx5pln0mi0gthZZ50lhyjQ+/X++++LYcOGiZNPPtkal0aj5dtQ1l9//XXVsqeDdTiSIqxnjB07Vuywww7ikUceEQ888ACNRiuIPfzww2Lo0KFi1VVXFf/85z/F3nvvLW666SYZbotPo9HyZw8++KAs02uttRZ9wvIIHHaPPfZYtUQIKRJ46xm+IuPHjxeHH364+OCDD9QaQkiR2GOPPVIXYYAirI/g1XXMI0QIKR7/+te/xC9/+UvZE4a3I//v//5PrSGEFInf/OY34p577lFL6cHhyD5CEUZIcaEII6QcZCHC6BPWASjCCCkuFGGElANnRFiZmTJlirjwwgvFBRdcIOcFageKMEKKC0UYIeXAmeHIsoK5gJZYYgnx61//Wuy2227ytfR2oAgjpLhQhBFSDugTliF442mNNdaQ8wD1FLzeShFGSDGhCCOkHNAnLEMw4/3AgQPFM888IydeveOOO9SaMN98842cORuvrcPw+84776QII6SgUIQRUg7oE5YhI0aMEAsssIDYfPPN5YSMCy20kDjhhBPU2gYQabvssouMM2jQILHvvvuK9ddfXxxxxBEqBiGkSFCEEVIO6BOWIcOHDxc//OEPxQsvvCCX0RMGUTZz5ky5rPnqq6/EO++8I959911p+M7U7bffzp4wQgoKRRgh5YA+YRly7733ilVWWUV8/fXXcnn69OliwQUXDERZKx566CGKMEIKCkUYIeWAPmEZgt4tiLArr7xS+nkddthhYuWVVxYfffSRihEP344kpLhQhBFSDugTljH4kOeaa64pxVj//v3Fo48+qta0hiKMkOJCEUZIOaBPmAN8+OGH4pVXXhGfffaZCukeijBCigtFGCHlgD5hOYUijJDiQhFGSDmgT1hOoQgjpLhQhBFSDugTljHz589Xv3oGRRghxYUijJByQJ+wnEIRRkhxoQgjpBzQJyynUIQRUlwowggpB/QJyykUYYQUF4owQsoBfcJyCkUYIcWFIiwF6lXRr18/z6qiroI0XbWKXFepdWFJ1Cr2eIT0FfqE5RSKMEKKC0VY8tTrMZKqqyYqVX9dvVoRUodJIUYRRjoPfcJyCkUYIcWFIqxnfPfdd+KJJ54Q9913nxRXqB/xf8yYMfKbvM3URRW9YJWaJ6/CoBdMaTDZW9boDaMII52HPmE5hSKMkOJCEdYzMNXPa6+9Jl566SXx2GOPiauvvlq8/PLLYurUqeLdd99VsQy6unzxhSHJiBDrqlVV75dcEFWKMJIg9AnLKRRhhBQXirDeM2fOHDF69Gi11D0h0eXBnjCSJvQJyykUYYQUF4qw3jN79mxx5513qqXusIgr+oSRFKFPWE6hCCOkuFCE9Z52RJh++7FfP19khXq/POpVrNNvRzaWbT5khPQF+oTlFIowQooLRVjv6VlPGCHZQp+wnEIRRkhxoQjrPbNmzaIII7mBPmE5hSKMkOJCEdZ73nzzzR455hOSJfQJyykUYYQUlzKJMEwvMW/ePPHtt992xF5//XUxcuRI67reGuYhIyQJ6BOWUyjCCCkuZRJhEydOFBtuuKH41a9+JQYOHNgn23LLLcUmm2wiBgwYIH/b4vTUNtpoI1GtVsVXX32lckxI56BPWE6hCCOkuJRJhD388MPiBz/4gVh11VXFKqus0mdDOmussYZ1XU8NaS2xxBKiUqmIzz//XOWYkM5Bn7CcQhFGSHEpkwh79NFHxUILLSQ22GADsf766ztlyBOEGHrpKMJIEtAnLKdQhBFSXMoowiB61ltvPacMeUKPGEUYSQr6hOUUijBCigtFmBtGEUaShj5hOYUijJDiQhHmhlGEkaShT1hOoQgjpLhQhLlhFGEkaegTllMowggpLhRhbhhFGEka+oTlFIowQooLRZgbRhFGkoY+YTmFIoyQ4kIR5oZRhJGkoU9YTqEII6S4UIS5YRRhJGnoE5ZTKMIIKS4UYW4YRRhJGvqE5RSKMEKKC0WYG0YRRpKGPmE5hSKMkOJCEeaGUYSRpKFPWE6hCCOkuFCEuWEUYSRp6BOWUyjCCCkuFGFuGEUYSRr6hOUUijBCigtFmBtGEUaShj5hOYUijJDiQhHmhlGEkaShT1hOoQgjpLhQhLlhFGEkaegT5gjfffedmDt3rvjqq69USGsowggpLhRhbhhFGEka+oQ5QrVaFT/96U/FzTffrEJaQxFGSHGhCHPDKMJI0tAnzAFGjRol+vfvLxZZZBFx6aWXqtDWUIQRUlwowtwwijCSNPQJyxgMQa622mpi5MiRYuONNxYXX3yxWtOaJ554giKMkIJCEeaGUYSRpKFPWMYcd9xxYuuttxbz588Xa621llWETZkyRRx//PHilFNOkXbWWWeJ3XbbTRxxxBEqBiGkSFCEuWEUYSRp6BOWIRMmTBArrriimDVrllzGkOS1114rf5tg/W233SZGjBgh7Y477pDi7cgjj1QxCCFFgiLMDaMII0lDn7AM2W677cRPfvITKagwtLjooouKjTbaSDz55JMqRjyPP/44hyMJKSgUYW4YRRhJGvqEZcgtt9wiTj31VDnUCCG22GKLiU033VQ8/fTTKkY8dMwnpLhQhLlhFGEkaegT5hBLLbWUqNVqaqk1FGGEFBeKMDeMIowkDX3CHOLqq68W48aNU0utoQgjpLhQhLlhFGEkaegTllMowggpLhRhbhhFGEka+oTlFIowQooLRZgbRhFGkoY+YTmFIoyQ4kIR5oZRhJGkoU9YTqEII6S4UIS5YRRhJGlK4hNWF9V+/UQ/ZZValwquBmH9+lW9WPmBIoyQ4kIR5oZRhJGkKY1PWFetIvpVDZnVVRMViK9KTfiSzBNqwW/3oQgjpLhQhLlhFGEkaUriE9YlarVwP1e9it6vitCdYqCrVstNbxhFGCHFhSLMDaMII0lTEp+wuifCDLWlhiGDYUlF3RNh7AkjhGQNRZgbRhFGkqYkPmFdolY1hh0tPmDoGYuKMpehCCOkuFCEuWEUYSRpSuMTFviARQSY9BWzhLsORRghxYUizA2jCCNJUxKfsOJBEUZIcaEIc8MowkjSlMQnrEG458s386XJvEARRkhxoQhzwyjCSNKUxCcMKF8wi+KSb0rmaHoKQBGWFI055Zp9BLtEraLEu7pftKjPkz8hcR+KMDeMIowkTWl8wtBYtmoou1vvGhRhydCYpgRiLOIj2FUTVXWP4H6penErStTXq+HpTgjpCxRhbhhFGEmakviEmW9HxtFOHHegCEueJmGFlzsC0VUVNQgxrdLqVfaGkY5BEeaGUYSRpCmJT1hknrAYOFkrMbHOG6fmmIP46qp5QkxHMHrJCOkrFGFumJsirJXLBKqiiItE8Hm+fH2aryyUxCeMIqysfPfdd+Kjjz4Sc+fOlf8/+eQT+fuDDz4QX3/9tYplwau4mt0H9ZcX/KFK9oSRpKAIc8NcFGGtXCZsbjX1elNFRhyiJD5h3s3a3KI2gSGmvNyuFGHt8cUXX4g777xTDBs2TNxwww3iyiuvFMOHDxe33HKLeOONN1SsCHhytN0vptCCSKNPGEkIijA3LC0RhofCl19+WUyfPl3MnDlTzJgxQ7z66qvyNx4k4wjXO40eskavlwrL2YtnZaIkPmHmzdnKKMKKxvz588W8efPEt99+K6ZMmSLuu+8++Rtmq9x0V742aCzphC9vDOPtSHWv+N8g5duRpLNQhLlhaYmwrq4ucdddd4l7771XXHrppeL2228XY8aMkecGdVUcIZcJo/c+6BHz0pXr8WBJIeYk9Akz4HBkscGT5tixY9USIe5CEeaGpSXCTEaNGiXefPNNtdQCQ3RJzGWLj2rIh5U4Q0l8wooHRVjPQVf/gw8+qJYIcReKMDcsCxF2xx13iNmzZ6ulGNCzFVJgHsbb200CTfbi52ekp0yUxCeseJRJhGFIsTcGMOQIvzBUoJMmTZJd/PgN0938tm3bMUKSgiLMDXNRhEVdJiqVxgtCwToV0IhLn1VXKYlPWPEogwj7xz/+IXbZZRex9957i0GDBvXY9tlnH/Hb3/5WbL311mKrrbYSm222mdh4443l74EDB4pdd91V7LvvvtZt2zHk7fzzz1e5JaRzUIS5Yc72hJHCUBqfMNMx33zDTYflbQ6VMoiwq666SlaCJ5xwghg8eHCf7ZhjjhHHHnusOProo63re2LHH3+82G233WQBIqTTUIS5YRRhJGlK4xMmu2XNQXKMn0N8BW+MeEItR2+PlEGEXXfddbK36sYbb5RTS/TUrrjiCmm2dX015A1CDD1phHQaijA3LAsRBpeJ999/Xy2RolMSnzA9yWYDf2qB8Dg53450CwidnXfeWVxzzTXytW2XDEIMPWoUYSQJKMLcsHZE2NSpU8VTTz0lnnnmmT7Zs88+K+2cc84Ro0ePFuPGjbPG64k9/fTTMs0PP/xQ5Za4Rkl8wiJTVKhhyKaZhc05VxyHIixbowgjSUIR5oa1I8K22GILseCCC4pllllGLL300h2zTqS35JJLynOL9oK4SUl8wsyPc2v/sLAPGHrG8jThJkVYtkYRRpKEIswNa0eEbb755mLFFVeU8dddd10xYMCAPlmn0oEhncUXX1xOUk3cpDQ+YYEPWESAhV/3zY9zPkVYtkYRRpKEIswNa0eEYd3KK68sNthgA2saWRt6w+6//36VW+IaJfEJKx4UYdkaRRhJEoowN6wnIszF/MMowtymJD5hxYMiLFujCCNJQhHmhlGEkaQpiU9Y8aAIy9YowkiSUIS5YRRhJGnK4xNWMCjCsjWKMJIkFGFuGEUYSRr6hOUUirBsjSKMJAlFmBtGEUaSpoQ+YZE5w3IKRVi2RhFGkoQizA2jCCNJU0KfMDVPmPkJoxxCEZatUYSRJKEIc8MowkjSlNAnTPWEGR/vzqMeowjL1ijCSJJQhLlhFGEkaegT5uF/RzL9yVq//vprMXLkSHHYYYfJxvy2225Ta7qHIixbowgjSUIR5oZRhJGkKbdPmNEb5g9P6k8ahT/snRSffPKJOPDAA8XJJ58sTjjhBFkRXXjhhWptayjCsjWKMJIkFGFuGEUYSZry+oQpsw9FenEqNfU7GebPn69+Nbj44ovFsssuK7744gsVEg8qLoqw7IwijCQJRZgbRhFGkqaUPmEQYS39wOR3JqtqIT2OPfZY+f2xb775RoX4zJkzR9TrdfHggw9KQ6V11llniaOOOkrFKCYUYaSsUIS5YRRhJGnK5xPmCax+tl6uelVUMpi6QveITZ48WVZEtsIyadIkcfjhh8tG/5hjjhFDhgwRO+ywgzjiiCNUjGJCEUbKCkWYG0YRRpKm3D5hIbpErZKuY75m5syZYrnllpPiql0eeeQRMXjwYLVUTCjCSFmhCHPDKMJI0pTHJ8x0wo+zDOaqePnll8Xaa6/dY0E1duxYirAMjSKMJAlFmBtGEdZp0NmB9rZFhwfcgcy2OLpcMMrnE+Zd0GoGw442XnrpJbHwwguLbbbZRoqxadOmScPUFd3BtyOzNYowkiQUYW4YRVgStBp1ik6mHl0uHuXzCXMIDCkus8wyYsMNNxQDBgwQ/fv3F5VKRcyePVvFiIciLFujCCNJQhHmhlGEJUG8CKtXvXCj5yu6XERK6BMWT1etFt9FmgDfffedtG+//Vb2fmmzTV8RhSIsW6MII0lCEeaGUYQlQYwIq1f9WQu06IouF5QS+IRFp6TQY9I2i+sidQ+KsGyNIowkCUWYG0YR1j3z5s0TH3zwgXj//ffFhx9+KD766KNg2e5aYxNhrdplZQUVYuXzCfOI6/FKuyesL1CEZWsUYSRJKMLcMIqw7vn000/FHXfcIW6//XZx/fXXy/p6+PDh8jN8s2bNUrFM4ocjJdGeL/aEJUK2PmHyTUn9aSKtwPPTCwYowrI1ijCSJBRhbhhFWHugNwyG+/WBBx6QbjZYtrnWBN9qrtREvVZpnjidIiwVMvQJw/CkfTwaN4Ub7012D0VYtkYRRpKEIswNowjrGZhYHC+ckfYpgU9YlJjJWmXvGH3CXIIijJQVijA3jCKsZ0ycOJEirIeU0iesXtVDkZr8zUVCEZatUYSRJKEIc8MownoG5rt85pln1BJph3L6hNnexMjZmDNFWLZGEUaShCLMDSu6CHvttdfEyJEjxZ133tlnGz16tLjwwgvF6aefLn/b4vTURowYIZ577jmV22JSQp+wYkARlq1RhJEkoQhzw4ouwi6//HLx/e9/XyyxxBJ9NuxnqaWWkmZb31NDej/60Y/E/vvvr3JbTEroE1YMKMKyNYowkiQUYW5Y0UXYFVdcIRZZZBGxwQYbyPz3xbAvW3hvDV+SWW655cRBBx2kcusGXbWKHD2rRHzLg7c+g1E15eZkiWtSSp+wIkARlq1RhJEkoQhzw5CnIosw1GOLLrqoFGG2bbM05Aki7OCDD1a5dQBjuoyQb7me3V/+9CeHb8w7GjMjg6KkPmH+iQr8wbpRqi5CEZatUYSRJKEIc8MowrKztEQY5jLTnxAE+rdtjjP0gjU6uqqBbuiqVRuCzBNq1YieaH4ZsEEJfcJ8p/zgRCpkF2M00GEowrI1ijCSJBRhbhhFWHaWlggbP368nO0fs/4PHTpU/seM/08++aSK0SBObEE/BB05NhFWi5+DtIQ+YTHzhHnws0VuQRFGygpFmBtGEZadpSXC8K3LOXPmiJkzZ4obbrhBzJgxQ5a/uXPnqhgN4nrCoCu0/1fjazwKY6jSRil9wurV5vFZ2RPGGfOdgiKMlBWKMDeMIiw7S0uEab755hvZC/bFF1+oEAtxPmEBnhgzFRcmge9mhK2kPmGmalXWzYlyDYqwbI0ijCQJRZgbRhGWnaUtwiC+MGfaJ598okLsaH9y9ILpnjHZiSO1RKODpxHmW5zEKKFPWDGgCMvWKMJIklCEuWEUYdmZqyKs05TQJ6wYUIRlaxRhJEkowtwwirDsjCIsOTL3CYuDjvluQRHWe3RXeNPUK/BRCHWbG5/wypFPZNGhCHPDKMKys7RFGLj77rulb1ialMAnzPKdyFiLn1DNNSjCsjWnRVgL59F6PXKHR16zzplrZGGhCHPDKMKys+5E2Lx588Ts2bPl9y9ff/31PttLL70kP+M0ZcoUudzXdLE98tedqCuFT1i7PVzsCXMLijAhJkyYIOewGTVqlJy7Rs9h8/jjj6sYzYTElO01arPHKyTY8vMQUnQowtwwirDsrDsRhmkl1l57bbHsssuKlVZaqc+24ooryv3hv219Tw35WnPNNaUga0VJfcLCjZH/tkP8jLYuQhGWrSUtwjBbM+y9996ThRhz11x99dVi8uTJ4o033pAVUByxszd3dfniC0OSphBTQ5TsBXMHijA3jCIsO+tOhKGXCed99dVXl2KsEzZgwABreG+sf//+UtBNnz5d5dhOCX3CMDyJJ37vfzXSEHGeMKdgT1gYOI1+/PHHaime+J6wBg2h5pWDGiLjwYQ9Ya5AEeaGUYRlZ92JsDfffFOsscYaYq211rJu344lec0gxFZbbTUnRRjIUITpGfMtIow+YU5BEdYAfgUjRowQ77//vgppQbcTCuoHEQ9TpHm/2RvmBhRhbhhFWHaWhghL0nInwtIcjvR9X0wRpoYnc9QCUYRla06LMI/WEwqawgyCzI+bp4eQokMR5oZRhGVnFGHJ4Y5PmGk56wKgCMvWXBdhJN9QhLlhFGHZGUVYcmTsE1YMKMKytbRFGBgzZoz4+uuv1RIpMhRhbhhFWHZGEZYsDviE5RuKsGytOxEGsYRrdOutt4phw4b1yjAVBd6IvOSSS8TFF18sqtWqOPfcc+Uy9o+pK2zbtWO33XabuOuuu1KfHZq0B0WYG0YRlp1RhCVLhsOR+fP/skERlq11J8IwhQRed95yyy3FjjvuKHbYYYceG7bbdtttxVZbbSW23nprsf3228v/WN5mm22s27RjSBdprbDCCnLKC+IeFGFuGEVYdkYRlhwZ+4SpnjD5NqTvD2Z7hd91KMKyte5EGCoICCbERW/WVVdd5YwhPzinW2yxhZg4caLKMXEJijA3jCIsO6MISw7nfMIab41xigqXyLMIe+utt6QI++tf/youu+wyaxpZGfKDQrj55puLSZMmqRwTl6AIc8MowrIzirBkccQnzHw9P189YhRh2RpFGEkSijA3jCIsO6MIS5bsfcK05WiWfBOKsGyNIowkCUWYG0YRlp1RhCWHdTgyXRGWr+9E2qAIy9YowkiSUIS5YRRh2RlFWHJYRRjpGRRh2RpFGEkSijA3jCIsO6MISxaKsD5CEZatUYSRJKEIc8MowrIzirBkyXA4shhQhGVrFGEkSSjC3DCKsOyMIiw5rMORZRZhs2fPFk888YSYO3euCukeirBsjSKMJAlFmBtGEZadUYQlh1WEpUfMZ4vq1UymqHj44YfFiiuuKC8WLtyrr76q1rSGIixbQ+U1ePBgsc8++6jchqEII32BIswNK4IIW2qppSjCMrCeiDB8Fzht3BNhcs6wdCdrxXf7UHjPOOMM+a1BCI6ddtpJzJ8/X8WI58EHHxTHHHOMWiomN910k7xBb7zxRllZuGQQiMcff7zYf//9VW7DvPfee/LTQrVaTc5Sb0sjS8Os+Wg8XnzxRZVj4hLoFd9kk03E+PHjxeGHHy5FWVF56qmnpAhDowuDmHHFkJ9VV11VDBw4UMybN0/lOAw+TYZ63LW8a4MIQ3th49prr5UibMMNN7Rum6UhT8svv7z8Zq6Nd999V4owiB3b9lnbOuusI1ZffXUxc+ZMlWM7u+22W0l8wozPFMVayt+TROWz8MILBxfp3nvvFUsssURThfvNN9+Ijz76SHz88cfSPv30U/nxZdycb7/9tux1iTM8QSN9V23WrFnWfOPbi3/5y1+kUDj77LPFn//8Z2fslFNOkcL5gAMOELvsskvTNcAyPge08cYbixNOOEHGt6WTlSE/MDytjR071noP4SnTdr1csDfeeEP+Rx6j+daG+0rHc9FQLm35huF6PP/886JSqYjnnntOHHroobJHrFVZx7mAW4OLhmuB/7brhXI+cuRI8eMf/1j0799fNqouGfKE3hgIghkzZlivAdYts8wyTuYfhjbmb3/7mzzXZr6xfM4554gFFlhArLnmmtZtszTkafHFFxd77rln03nH8oQJE8QvfvELKYBt22dtEO8QkU8++WRs2UX4dtttJ9v+NLEORyYuwjRdNVF1ZJKwoUOHyo8of/jhh3IZQ0OLLLJIU+8Enob33ntvceCBB4qDDjpIVsr4EDNuQPS24Cktang6w38o8ZVWWkl2qbtkuEHxH8eAJ8jocWAZH8BG5Yb8Y8jWNUPljLzhXOvzDcMHtjfbbDO5HtfXtq0LtvTSS0uhiGFTnXccB/KPp0vE0dfJJUOecN8gj9H7BseCYTyst23rgqHRgOEBw7xvtOH8Q4Dh3nrppZdkI7TuuuvK8GhcGM4BhmRQ4UevsSuGvOEYzHsNhmWIGDS2KOsuGnyqkP/o9dLlHmUcvU22bV0wPNijjo2ee9w3KENYb9vOBcO5R5mJ3vu6jkUdBrNtm7XpvKFH21Z2dV3785//XLolpUnGPmHxdNVqqQ5H3nrrrbKCwrAkmDJlihRhL7zwglzWfPHFF6EnZ/SUDRs2TPbEdHV1ST8ym7388svyYiPekCFDxLHHHuuUnXzyybJyuOCCC+RTZjT/r7zyipg6dao8Ly4axDIayWi+tWGdbTtXbNq0afIcR/ONewqCH0PjJ510kvXaZWnIEyqvww47rOm+Qd5vu+02ORyA4eLjjjvOmkZWhjzBxwuNH3pLzbxrgw8JeskhTtAThh5v+E3Z4sJwzLvvvrsc0sNDF0SqS4Y8obcFvbC2+gr3IO5FlHVXrVU5Rz1r28YViyvnMNfPPfKG82vLOwzXxYxrbuuCIX9x5x6Gso66LO2eMJCpCGt8sDtq6fqEoWKF0keXJIAaxjK67bvjoYceassnbK+99hKnnXaa9GGCb5JLBp8v9OgNHz5c5Za4AoQOelzhj2e7dlka8oS3Us866yyV2zDjxo0T2267rfR3ge+bLY2sDHnCMPsWW2wh/UDjgPuB6RMGH8NWQNihRwPCLeqbkrUhT4sttph8wYYQEgYPUHfffbdaSo8mEQa/HzgPmpYM+GyRXWyl3RP2/vvvi2WXXVY6SgP0PqBy/u677+RyK9p5OxLp4AKjQb3iiiusb8plaaiU0ViiR5C4BXps8FYSRIzt2mVpyBOG5/FwYQPTvWDo5fLLL3fuzVTkCX44GEqBf2ccPX078pBDDgmGnaJvaWVtyBNEGI6dEBImjSkqotoKeqtJhGG4LGrJ0CVqVXc+2o1eIIwfb7TRRtJPBJVuO1CEkSShCEvGKMIIISZpiDCbvspQhHl01UTN0uWVdk+YBr4h8GN5/fXXVUj3UISRJKEIS8YowgghJiUQYZj/y+b/ZbN0fcL6AkUYSRI4tFOEdd4owgghJqXoCWu3hyurnrDeQBFGkgQ9YXgrD47keJ3ZJcNLJvhSwamnnqpyG4YizC6GsjKKMELicUaEpeeYXwwowkiS4N7aY4895Jt8eAuxr3buuedKs63rqeFTUHir9sQTT1S5DUMRZhdDWRlFGCHxOOOYnyZxPV7B1BUVdxz346AII0ly0UUXyQlDd9xxRyl4+mJIAxNdwjD3mC1OTwzpoWGPa9QpwuxiKCujCCMknjREmI2MRZgxT1gguDB1RUXIyfQz+ph3T6AII0mCOazw/cIPPvigz4YvQmAyQhh+2+L0xDC1C/IWN88WRZhdDGVlFGGExOOMCIOvRzpEPtTdVRMV+c1IQ4SpOC5DEUbyxDPPPCMtDSjC7GIoK6MIIySeLEQY9FaGIqwuaqFeLj1vGEVY2kYRVh7wEVuIozSgCLOLoayMIoyQeJwRYemhRZeiXhX9gp4w1UOG3rFKDb+chSKM5ImoCJs/f7761Yx2Fwi5BKBMKhcCM7xeVW4Fsgz7mCLMdt9laRRhhBCTUvqEmRW69AmDEJO/K0G4Uac7CUUYyRNt94QF7gEQWLpn2qOrSz04eQ9L2o/TK7e6nEKM6d/sCbOLoayMIoyQeEroE1YMKMJInnj22Wfb8glDL1jwAGR7QcYTafprF121qiHSaqKqFiDCttlmG/lNVjT8qFt6a9g+arZ47RrydN5551GEEUIkJfQJKwYUYcR1PvroIymI0At24403StM9Yp988omKFSZOWIHo0CMEWyDSjLiPPfaYFDAXXHBBMD9ZXwyi6fzzz7eu66khTyiPECY4P3FQhBFSDkroExYPZ8xP1yjCig16esaNGyd7wSZMmCANvxH26aefqlhhcdVtT5h6acaPAj9OtW3wUo0QkydPFhtvvLEYOHCgHJbsrVUqlUBIrLvuusF/iCNb/HZt0003lT11X375pZ9hCxRhhJSDEviE+RV1ULHLSlxX3FHjtyPTNIow0kScT5hB3XtYCgd7ZbxRwMW3334r3nnnHSlc3nzzzR7bW2+9Jf+/8sorYtq0aWL8+PGi5u1zypQpYurUqaKrqyuI01vDXGetoAgjpByU0icsfsZ89oSlaRRhxIbuGUMvmO4ZC3rLPNN6S79FmfTDEyaFvfPOO9VSOlCEEVIOSuoTpoYx1FtWfgVvf+p2FYowQtIBs/zffvvtsoetO7QwtL1QELyR7VnVe+CzTbmhoQgjpByU0CdM+5RY5gsLPmHkPhRhhKRD2yKsxVBqVx01jqKONzwtU24YUIQRUg5K4BMWRc+YbxFh9AlL1SjCSB7AW4wQYfPmzVMhdrp/qcAn5NPmCTc95YYJRRgh5aCUPmH1arQnTA1PGs69rkMRRkhymDP6Q4QNHTq0DREWP71Gg8Zn06JTbphQhBFSDsrtE2ZajgQYoAgjJDkgwh599FExfPhw2QuG8jNy5EgxbNgw8fzzz6tYYSHVVk8YhiJDwdo9IgxFGCHloIQ+YcWAIoyQZJk7d66YM2eOnO4Cv/Efy3ETzaL3q+fTa9jDKMIIKQcl9AkrBhRhhLiHOb0GCPWO2YYiPbN1wlOEEVIOSuIT1qj8WsF5wtI1ijBC7FCEEVIOSuITZvEBsxrfjkzTKMIIsUMRRkg5KIlPmKUnrMlBlj1haRtFGCF2KMIIKQfl9QmziLA8QRFGSHGhCCOkHJTEJ8wCRVjmRhFGiB2KMELKQUl8wixQhGVuFGGE2KEII6Qc0CfMgD5h6RpFGCF2KMIIKQcl8Qnj25EUYYTkB4owQspBSXzCOE8YRRgh+YEijJByUF6fsJxDEUZIcaEII6QclMQnrHhQhBFSXHojwpZcckmKMEJyRkl8wooHRRghxaW3ImzDDTeUosclq1QqYvHFF6cII8RCSXzCigdFGCHFpaci7He/+5343ve+J8UOep36aksttZQUdbZ1PTXk6d///d9FrVZTuSWEaOgTllMowggpLj0VYU888YS46qqrxA033NBnu+mmm8QxxxwjTj/9dHHzzTdb4/TErr/+enH11VeLadOmqdwSQjT0CcspFGGEFJeeirBO8+STT4rp06erJUJIUtAnLKdQhBFSXLIWYQ888IB4/vnn1VJ3dIlaxTLPYldNVIx5GKtqZVetIpcref5kCSEdgj5hGfLll1+K8847T2y99dbSefXkk08WX3zxhVrbGoowQopLvkQYgBALi7Cuet0LVegvlECYKTVWr1Zy/ek4QjoBfcIy5PPPPxennXaaGDZsmLRll11WHHXUUWpta3oiwiDurrzySnHZZZc5Zddeey1FGCEWshZhDz/8sJg6dapaaodmEWZSr9WkIEMvmO4R81QYe8NI6aFPmENcd9118o2kzz77TIXE89hjj4nBgwerJTsQYTvvvLM44YQT5Ovhl1xySa8MvVZaOOHimUIKbzzZtmnH4Kw7cOBA6fxLCGmQhQibO3eu3N+kSZOkQ/2oUaPkb1j3PfStRFjjiyVdtWqj96urJqoUYaTk0CcsQ+bPn69++eA182222UbMmzdPhfhMmTJFHH/88eKUU06RdsYZZ4hdd91VHHnkkSqGHaQ/aNAgsc4664jNN99cbLbZZj22LbbYQg6Vrr322jKdAQMGyP9Yxu9NN92012lju9VWWy2TG5AQl0lThOl66J133pE9YI888oh82xIPelh+/PHHxaeffirjaOpV5esVdGu1EGF6KNKDPWGEhKFPmCPce++9YsEFFxQTJ05UIQ1mz54thg4dKkaOHClt9OjRUpR1J8LAnDlzxCuvvCJeffXVXhnekHrxxRfFhAkTxHPPPSd7vnDD4Dfy2tu0sR1sxowZcliWENIg6+HInhMvwvRQpIQ+YYSEoE9Yihx++OFik002EVtuuaV4/fXXVaj/OvhCCy0kfaTaBU+n3fmEJQEcdt9++221RAhJgryJsKBnrFLzRJfR22UMRWp0XPaCEUKfsFTB20bo4kdXv/b7gqhZaaWVxI033iiX26Udx/wkGDNmjHjttdfUUhx4KkZFG/NkHBnKaB7aIKTc5K8njBDSG+gTliHjxo2T4gM9YxA3w4cPl86wUf8LG1mJsPvvv18Oj3ZPzPBEvRo8JUN8VauRZeowQijCCCkJ9AnLEIgwTNGwyy67CMwV9qtf/UrsuOOO4q233lIx4klThMGv7Nlnn5V+YJjbC0IMPmKTJ09ueomggV2ERd+OqvQz/EL4thQhEoowQsoBfcJySpoibNasWeLBBx8Ujz76qHjqqaekPxreoHrmmWfEt99+q2JFiRNhlYYviBRhhm8IRRghEoowQsoBfcJySlbDkXE0+3XFvS1VF1XEk4ZesOiyikZIiaEII6Qc0Ccsp7gmwpqJE2EaT3yFHMCiy4SUF4owQsoBfcJyiusiLOgZi7yyjuFIv9fLF2jRZUIIRRghZYE+YTnF/Z4wQkhvoQgjpBzQJyynUIQRUlwowggpB/QJyykUYYQUF4owQsoBfcJyCkUYIcWFIoyQckCfsJxCEUZIcaEII6Qc0Ccsp1CEEVJcKMIIKQf0CcspFGGEFBeKMELKAX3CcgpFGCHFhSKMkHJAn7CcQhFGSHGhCCOkHNAnLKdQhBFSXCjCCCkH9AnLKRRhhBQXijBCygF9wnIKRRghxYUijJByQJ+wnEIRRkhxoQgjpBzQJyynUIQRUlwowggpB/QJyykUYYQUF4owQsoBfcJyCkUYIcWFIoyQckCfsJxCEUZIcaEII6Qc0Ccsp1CEEVJcKMIIKQf0CcspFGGEFBeKMELKAX3CcgpFGCHFhSKMkHJAn7CcQhFGSHGhCCOkHNAnLKdQhBFSXCjCCCkH9AnLKRRhhBQXijBCygF9wnIKRRghxYUijJByQJ+wnEIRRkhxoQgjpBzQJyynUIQRUlwowggpB/QJyykUYYQUF4owQsoBfcJyCkUYIcWFIoyQckCfsJxCEUZIcaEII6Qc0Ccsp1CEEVJcKMIIKQf0CcspFGGEFBeKMELKAX3CcgpFGCHFhSKMkHJAn7CcQhFGSHGhCCOkHNAnzBFefPFF8be//U1Mnz5dhbSGIoyQ4kIRRkg5oE+YA3z66adivfXWE/369ROXXnqpCrUzf/58+R8ibPDgwfI3IaRYUIQRUg7oE+YAQ4YMETvvvLNYc801Ra1WU6Gteeyxx9gTRkhBoQgjpBzQJyxjJk6cKJZZZhnx8ssviw033FBcfPHFak2DOXPmiHq9Lh588EFpDz/8sDjzzDPFkUceqWIQQooERRgh5YA+YRnyzTffiIEDB4qTTz5ZLvfv39/aE/bcc8+JarUqRRfsqKOOEttss4044ogjVAxCSJGgCCOkHNAnLEVGjBghLrnkEnH55ZeLjz76SDrir7zyyuK9994T3333nVh99dXFRRddFPh9teLxxx/ncCQhBYUijJByQJ+wFMEQ4j777CMOPvhgWcnutNNO4mc/+5nYYIMNxIABA8QCCywgFl10UTFy5Ei1RTx8O5KQ4kIRRkg5oE9YhsycOVNMnTpVTJo0Sdryyy8vhRV6xrrj/vvvlw79hJDi8fXXX4tNN91UjB8/Xvzxj38Un332mVpDCCkSe+21l7j77rvVUjrQJywG+IRhqLIdHnroIbH55puLa665Rlx77bWp2S233CJuvPFG6zrXDflG/m3rXLfrrrtO3HrrreL666+3rnfdbr75Zmm2da4bzjnOvW1dUnbBBReIFVdcUT6c7bnnnuKss86yxkvK4Cpx0003Wde5bjfccIO8XmnXjZ0y5B3HYFvnuuGewb1jW+e6ZVXHrrTSSmLMmDGqZU8PijALb7zxhpg7d65aag2GKw444ACx7rrrio022igV23jjjcXCCy8sVlttNTlUYovjqiG/8L/DcG/e8o7zjjdnMVy99tpr5y7/6NFZeumlpeG3LY6rhnOvXQVwDbBsi9dpQ7mG2wJ6wC688EJ53SuVijVup22TTTYRiy22mFhhhRVyd71QNtZYYw2x0EIL5a6cwHB/Ie84hrzlH/cNRnOWWGIJ+dsWx1XDeV9//fXFggsuKMt7WuUc+9x+++3Fa6+9plr29OBwZIeAQz8c+dMwgDczH330UfnbFsdVA3jaOPHEE+VvWxyX7fPPPxf77bef6Orqyl3+AaZe0dOv2OK4amD27Nli0KBB4ssvv7TGScJQrk1scZIygDe2hw4dKn/b4rhq4NlnnxW///3v5W9bHNftoIMOkseQt/wD9IKh1xbY4rhqAB0g6Nh466235LItXqctWs7Tgj5hOQaz9D/55JNqKV/Aj+7Pf/6zWsoX8BHaf//9xeuvv65C8gW+BNHd1yBc5e233xb77ruv+Pbbb1VI8Tn11FPl29x5ZMKECeKQQw5RS/kDAhLHkEduu+02ce6556qlfPHJJ59IAfzuu++qkOJCn7AcgxcHMFt/Hrn33nvFSSedpJbyxRdffCF+97vfBT1heQNTs9gmIs4DeDMRbzV/9dVXKqT4nHLKKeL2229XS/li3Lhxcl7FvAIhgGPII/C5Pfvss9VSvvjwww9lTxgeusoARVhOoQjLBoqw7CirCBs2bJhayhcUYdmRZxGmhyNLK8I4HJkP0M2PzyblkbvuukscffTRailfwCds9913F9OnT1ch+eL8888X5513nlrKF7NmzZJz+ZRJhB177LHSvyePPP3001I055Xf/va38hjyCN4szKvLxwcffCDfRNY+YUWGPmE5Bn5VefVLwvc58e3NPIJPXN1xxx2yosgjTz31VG4bFnzdAhMoz5s3T4UUH0yB88ILL6ilfIEXKUaPHq2W8gceFnEMeeT5558PXtzKGxhtuPPOO6VvWNGhTxghhBBCSEZQhBFCCCGEZACHIwkhhBBCUoY+YYQQQgghGUCfMEI6CGZeJoSUgyKU9zweQ9HqWYowQgx6U8ApvgghLhNXR7Huyh4ORyZKXVT79RP9olapiY5P9dlVE5V+FVGTCfv7rdblmszBZ2Ywt5M28ztdmPLB1XmfMBWCrZKK5jcaB8ebdeWG/ZvnGcv6XGuLTvWAOPguY1bfUdO0uh+QPxs4FnxSKhtYznHvRMu5+XkpfW+5SFw5R3lphavlHMdjXodoOUd8hGedd/0NWBvInw3Ej1uXR+gTlgpdolYxK0p/uV9Ha07dCOjK2R3efPNNsfbaa4s111xTGr5WP23aNFmQ8BHyddZZR6y66qpyYkRXvhWGxvwPf/iD2GCDDULzBGEm5wMPPFDmd9NNNxX//Oc/1RofVHZ77723WHbZZTP95hzmMUMe8f04DT6avsIKK8hrAcN6xNNgVvZ1111XrLzyyvIYMClt2uDzPDivuE8qlUpoMmLMlbXllluKVVZZRebvnXfekeFoKDEBLa7VGmusIWfa1uvSpdzl/IknnhDLL798cH/hPrrpppvkOkwcuuGGG8rrg/+uzEIPEYUvd6AsoJ4yueCCC8Tqq68u70PMrQdMwYDZ9FHOH3jgARWSPphrEeXhxhtvVCFC/Otf/xLrrbee6N+/v7wOK620khg+fLhaK8RFF10k61xciz322EN8/PHHak163H333WKTTTaReVxrrbXkF1Q0mAsQ3+bFNcHEzHPmzJHhKOf45i2uB7YzP/CdZ+gTlgrRytkDT7OdfkoOPSG7w0svvSR+8YtfiBdffFG8+uqr4pVXXpEC7LPPPhNXX321ePbZZ6VgGTBggNhrr73UVtmBCQLxWaKFF15YLLLIIuK1115Ta/yKFwJBf5h4tdVWC1ViN9xwg6yYf/rTn2b2NQM0eMstt5z4/ve/H/pQ9+WXXy4233xzOdM/DEIYohI88sgjYskllxS33nqrvD7/+Mc/5ISJaVOv16UQw2S+xxxzjMwTGkfkBRUvrstzzz0nGxH8Btdcc428v5Bn3EtoOFGJp0+5yzkaepRh8/56//335bpRo0aJe+65R17Xww47TN6fWX+SBg8ZuE8WW2wx8eMf/1i88cYbao3/8WuUfZTh008/XT68aDEAhg4dKsOwXVbf9bz55ptlXfNf//Vf4sILL1ShQtZXEMOTJk1qKueob5deemkpglAX4/iy6FWCcMVDH+6HM888U/z3f/+3mDJlilyHehUP6uPHjxfbbrut2HnnnWU4rgmuFR4mJ0+eLB8YISKLAEVY4jRXzvVq8xOyDNPDGGpdV63SCDMrc1kR++EVXRublXO0og6WjWETvX9bWh0EIgzCpbuhomuvvVZWHi50kaOHCDM2L7HEEoEIQ6MBYYYKDGDG/EUXXVTGA/iuIUQZvtmGp0/MdJ4FqFifeeYZ2SDiqVcDEbbbbruppTCDBg0KxXUBXIeFFlpIHg8E1s9//vOgpxRiDdcCQv6cc84Ru+yyiwwH+EzO9ttvr5bSpPflHFjLeifLOUiwrEOEbbXVVmopHpSTn/zkJ5n3hqE+0uUcYt982EKP66GHHip/Y+gOYkf36qGnCeUcQgy9SVl91xOz4aNcbLTRRqHPkOE48MCCsmGC5V/+8pfi73//uwpxA/RwQfCiXoUghNDClwoAhBgEGs75lVdeKXv2NIcffri8TkWAw5GJo4YldKUYrRgBKsdQxVsVdTn0gP8+XV7D41ebSE9XvIgTrZCjQxZGhazTq1fV+pi0OggqBYgVVAz/8z//E+p6Ntlhhx3kMJMrQMigodeVM5YXX3zx0Ie7UQGefPLJ8je6x/EUh+50xMtKhGlwvk1hhSfnBRZYQPYi4Tpcd911ao0Qm222mRQvG2+8sRTMuhLMEnyeCCIYvSn44DiejjXoHcM9hYboww8/FDvuuKPYdddd5XcWcQzZfFy9t+Uc2Mp6J8s5FpIt6yjX6AGG+Me9V6vVQr5I+uEKjSketnQvWdagoYfA1+UcogAiCz2smoEDB4rjjz9e/kbjj3sNQ5no0cv64+ooz+eee65a8j8VhXKDMo5e4SuuuEKGo8zg2sAFBGIG60x3hbSIPmTj83s4/xDn6BmDCJs6dapchwffZZZZRj6IoecSw5Ooq1DnQvAjft6hT1gq+JWzWR/7T8ONSjdAVpqNdfqpOfTUKithXdn6JtMOKufIbxC3XI9Jq4NguA6+U+gRO/LII0NdzxpUFCh8M2bMUCHZ8/jjj4eGIzFkhzyaPmJ4EkOFgLjwzcCTHJ6cIcKy9AkDURE2c+ZMeR1w7jHE8h//8R/Bd/3Qc4dufwwZ46O/Cy64oByWzArkdamllpINOYDfDp7iNVroogJHjyR6wuBrhAobx42hlvTpfTn3g/zyF+7xapTLoGz2ppwHcS3pdQj452A4GA3oX//6V/Gf//mfcmjcBPcXyn8WjX8c8PcyH7Yw9I2eLzOPeECEwMfQHsq5FpC43+IeKpMgKmAgciHCzJ4wuFPggRH17WWXXSZ+9KMfyd4+PKz88Ic/lOIL346F6wR6midOnKi2TB/4buJcaxGJfOFa6IconGecY9RTEMdwB4G4xDGjzor65OYR+oSlQnPlrCvERph6ipUB+G1W3PoJV4XJbS0Ve1OF20blLEWYJa0EwVMwfBM0qCBQGWTp4GojKsLgY4EnTP30hQoRPWEYDsPT2YorrihFzwknnCCPB/4ms2bNknGzICrCoqBh0b5TeELG8WlQ8ZnXKE3QmKOhwAsQGogx5FE3QhBpGEJCY7P77rvLXjyAhgYOv6ioUWmnS1/LOTDKuty2Q+U8iJteWYfPHu4xDa4ZGs4hQ4aoEDeACDN7wvAQhZ4iszNiiy22EGeddZbscYVoQLk644wz5HZ77rlnZj0yNhEWBa4G6EGCX9gPfvADKcw0uB6m32iaID9wskf+NBDwqGPx8XGA3jHURaibcP5R38JNAdcID/TwBUWZzzsUYYkT94TcqCylP0gQQVfOda/x0bUpttHx/fSCJ2bvqVpu2qvKOSatDmI+vcGnBz0YeLJBOLr84Vfx2GOPqRjZo/MbFWHo0cPwgx7GQ68d1mPYEcNlGIqEqIEo+NnPfiYr7iy7y1uJMFTecGzVDSIcXPUbVHj6RONivjmZFujBQkULp3wTPCFD2OonZPSwoAGBszQaxbPPPluGAwwX4ek/6hOTPL0t5/7v5rLeyXIuFxIv6yYYwjv44IPlb/RY4H7DA4trPPnkk6GeMABh8Otf/1r+fu+99wKHcJQnXc4RB8P7EP0Y0swCLcLM4UizvgV4QIR/G4ZP8cYqhiMBepMxpJ9FryTKOerHI444QoX4oMyiXGuhCLcItBeffvqp2GmnneQb9Jr77rtP1rMQanmHw5GJop9smy1UAcrKMhLHe0oIhZkbmPH9mllWsH5cbzv9W/qfmOtQ6RvLWN+UVmfBEAXeiEIFjN4MDB2hlwLCC/vEkB7uOTSk6PFw5ckGfggYssMbRho4t+PtIjwFw/cIT8HRSg/5xxtL+rX2rEBPkSlO4BOGChgVNob20FuE3gkAB18sn3LKKXIdrknar67DURpDPXir8y9/+Ys0DJuigcOT77777isbcrxNhd5UPVSJ6Skg0OCz86c//UmeewxfRq9LsvSlnKOMRrbXG3WynFvT6xwQ7X/84x/l/QV/HVxLiGb48kDE4BrhYQVTP+Aaar+frIFf4fe+971QOccQHco5BD1EDHrAbG8R4u1IvPmZFdovDeVWg7eHUd+i7G+33XbyOuiHQTy8QLigrEA8YioLiMw0gXDEfv/t3/5NlnEMXaOco1cb4MEcrgh4QEQ5Rw8YgOM+7iH0kOPY0EM2ePDglMt557EOR1KEkU6C4aWjjz5aNqIQMfotSfiHoNFERYeChfXoYk67UogDDQga82h+RowYIYe/UBHA/yIKfJTgV5WlTxXAEAXElQaVHM7zfvvtJyu26JxsGA7GcZ122mnBK+1pAmGOc4qnY/Sg4EUHTFkyduxYuR7DEKi00QOBN1BN8LYknvZ///vfh+ZEIumBIaRqtSrvr1NPPTXooUAvBkQXyjl8enQvkm50swY9YCeeeGJTOcfDI+5DlGXbgyFEGY4ToicrIGhQJjBfmAZvEh533HGyPoW40Q9aGrh/4BrBlzWLaUKQ50suuUTeD2Y5R8+WBm+eIo9Rlwj0iKPNwFA3HirxcJZ3rCKMEEIIIYQkD0UYIYQQQkgGcDiSEEIIISRl6BNGCCGEEJIB9AkjhBBCCMkIijBCCCGEkAzgcCQhhBBCSMrQJ4wQQgghJAPoE0YIIYQQkhEUYYQQQgghGcDhSEIIIYSQlKFPGCGEEEJIBtAnjJBc0CVqlX6iUutSy2mT9f47SFdNVPpVRGcPJYnzk8I5r1dFv2pdLSSIPOf9RLu7qlc7fX0IcReKMEIypKtWEf28BirO/EaYIqwjKDHQjyLMF2CVmreXhAnOefsiTB97GvqQkKzhcCQhGQIRFjQ2ssGqiqDt8RrK3Asf10ikJ6xDeNc7FeGBc5CGANMoIdazY6uLqqvXiZAOQZ8wQjKmq1ZriK6oCPN+1dgKdRZnRVh6vT/1atq9TBBUvdhnWsOlhGQEfcIIcYkmEaaI9iQEQsJv3OTQpVzZWG7uQfMb+fAwZzNooHWcfjov1v1j2Ugz1FiG99VqnTUf+vjq/n70sFl06FYm221egHGepJkizMyPEd6Tcxw9Px7W8+jR6hiCcByvJc3Wee3uHGiQf/MeM9P0wkN5UfuAGMKyvA5m/Oj1i1vnnzM/S0YcdV3jzpV/XGZeCSkeFGGEuIKt0TEaxeYGW8XVjWRo2UzHb/iCdlml0dROI9wIlL10LfevGmkZpkVBZF8yLzHrbPkw0zeHzEL7iDbcMFtegL9PLQh8ERROJ7zOO29mHro7x0bc0HEZBxX0dtqOIThGQ6jY0vToPq9x58AA+TbPq8QUSQDL4e3rVRx3q+vXal04/a5atZE24gUbYdHoGY6mSUgB4XAkIa4gGy7VyIeINJLRRratZd1QNyzci+Gh4zW1erZGOrqs9mdt5BU9ykdYBDQR7KdFXuSiEktqMZR20378tGR+outaLkfyINfZzmOE0LmyHUc0zZi8Wrc14zaQ4s1yfWR4Y2dS/DSW1bC4Pq6INc5XzLogf2FBLGl5rizxCSkQ9AkjxCVkg5SUCLOla0HGVY2o0Qg3N/L25bhGXtJuPqL5D+HvS+YvVoQ1lpvyY6YtBZq5H6PRj+ah5XI0Dx5yffQ8aqLH0AiLO46Wee1uW4PY6xM6LzXvP9Lwl4OeKxkn5vq1WqfyI4/XFif2XFGEkWJDnzBCXCK2IYs0qmaD2fayvVGORW3TXiNvLEd7nkzazUc0/xK/QQ7SDnqRWudNig4zP2baTfnx9yGXo3louRzNg4Hah38e445BLrQ8jpZ57W5bk9A+w8jh0aonwDzD+mC5phJqyoNBq3VGfvw0rZGCNBqiyzxGQooJRRghriAboaj4ALYGuV2BACKNP/Aa46YeBm873d4CCJgeizD1O9TQBum2n4+m8wDxENlOigkZt0Xe1PogP6G0VX60KJHr1D6ieWi53LxP63mMPQa4u7c6p6BFXrvd1gTrIudWI/NnbBdd1nmwXr9W68z8+L+Dax53riSIa6RHSAHhcCQhDiB7CLzGSVujIdKNGwyNp9+ItbdsNmBmOp7ZWmjZsEfjRPffXX6QkBnmWajnpbt82NIDkTSbLC4v2NQXE9IqXiMfWt9d/m3phpcrofPhbW49j8DczjB1foJ7oFIV1WiaElte27keYbAf2+WXaaleMJ/oMmh1/WzrwseMoMa97t2fsefKA9fNnlFCCgF9wgghpGyEetFcBYLOLiIJKQr0CSOEkDKCXqZQD6VL+D1q7AQjZYAijBBCygh6xBxUOvHDpYQUDw5HEkIIIYSkDH3CCCGEEEIygD5hhBBCCCEZQRFGCCGEEJIBHI4khBBCCEkZ+oQRQgghhGQAfcIIIYQQQjKCIowQQgghJAM4HEkIIYQQkjL0CSOEEEIIyYDEfcJCX9S3fSU/BL62rz8qa/7uKz1Nq5P7tuF/F02eC9u32+THdfX5in7AFnkztq1XRbVupGda6DwnfUx2umqVlp8f6W49IYQQUmQS9gmDQDAbf2+5av9oLBrkfkoomL/7SifTah/vOGut9uiJolgBZgiv0LIvwALRosSav9z+ee4M3R2fRyh/FlqubyN9QgghJOckPBxpioO617BCFvhiooLf+JK/VUiYvxWq0Q7iY1tPaPi9QEbcaLwgLd2L5IuaQJzp+FXvt4yveo2awg2s2zTS1sfVstfPIsKQJ3leDHSYzG9serbzbKKOCT+R9+C84RzpvONYqt6+ao1luZ3lWoWOL3LsMi9+2kH8EJb10Wtmph9dRwghhBSAFHzCwg1uIDBkY+//hrjwG1dTSJi/fXQ8X5R4QkOm2xBUuoEOx8M+jLSkAAkiCnS2BNt6edLbQYDUIuEmzdt48bEriAcvoI59RzcKYRdh9apxjhQyP15ajeOxEXOeFfqYvFSazpsfrn9jnbGMY7BcK/P4oseOODo+jkdFC7Ct1+nqdeH0w+sIIYSQIpC4T5jXdBpiyuihsTTs4bjm7wZotAORYQiqRho+oXiRtHTDX69pEaSFSXTf0XCT8Dq9P2kQV6bYs2IXYTgOKXwMtPiwrWtgHqOtJ8xYb+Yteh2qjeUgnu1aGWlEj71W1T1iRnyDesz6uGsLwteTEEIIKQYp+4QpjEZWigspZsy4zdtp8YT40YY62piH4kXTwnZGg97liTG5LkjPj19rCm8Q3SboDdJYtgkTEWFe/Ko+pmBYzw+P9QnziD3GJoz1Zt4sIkwLvbjzLK9VKCx87Dj/ZppREWtbX21xbZuvJyGEEFIMEh2ObAyRGcJCov2IfJPtLYazvN+yoTV/K/wG2wurNBpuP12VlhI10Xjwc2pOS4ko/PYafJ0XMx/w9wqFGzRtYx6Pn4i/jN8QFKHjhyBScQOLCi9LOAit08dkphc9zwrjHEDU4HfjrUqIpPD1kBaIRMu1Mo/PXB9d9syPb9K8vumaGek3r9NphMUdIYQQkidS8AlzEa8Bb1YGyeIJRU/zuI8n1kyxSgghhJBkSMEnzC38XqCUe1DQe2Xx/3IP3TMW05tGCCGEkI5SKhFGCCGEEOIKJRyOJIQQQgjJlsR9wlo6oPcK0yG7r87ZhkO7HC6MLtvoZp9wgO+Yv1lPj69350M76scfc28wnf5doK/3igvk5Bi6KQP6fqPvISGk7KTgE4bG2Gg4+ugf5b8p18mGyGvYQvnpS0OnhEeoAfLCevn5nb4da5v7xfVI7CWFyLXPHb2/du6R1rHgmkfLgIEh0Mz54gghpKxkJ8KM6RaCOluHyc8BQRBhvVlZm+kpwSQr9ujni2zb2gSWFxYrwrpLQ69XhoOQosbIC/Km1wWohkql2xBb0f2Zx6q38SzIb2P/fq+Ckbdgv3qajei+PIzzH+TP266CCVu9sNCHwc1rFvfJI5mAiZl/k/Bxxh6/7f4I5c8Iq5mfWlJhoXj63FiOyZYm8MIb58Z2/g2s963R2xPaR+Q4JZEw7Nt6TzeOL/6eV2YeTNvHotLwwvHVgmAbuT32E817dNlD3iPeNvqcGPvAtQ6yhXPSOAGEEFJKEvYJMyp8abrBaFTI+K8r46CSRgXtNeCNBinYykvPT8NvvL1tZfp+I9BI07atjUjDZeTRloa/T3UMQSOCPKlGSDY8jbz088KtPU26oVK//c8nRfcXPlZ9jjCcg9/6WDVm3kKfTbLsK8BblpPEShoNsH8o0X02fyqqca7CefFp5L+JNo5fp9nIRzh/Pvr6NfIRCM9I4484+BRV+JiUeAul6RP9dFL0/JvovCLvmM9MH5pP9Lza7iszTIur6D2tz7cuU+H1ct8yEeN+VPTkWBrpIK6eT8+TXzIP0WvUfCxeoL8vy7Qs2J+OZu6HEELKSOI+YV5NHGmI0SA1GghUyhA+jcpYNzB6MlZlQSNppqd+Gw26bpB0uuFtbXj5Ca1H/vz07WlE9x9ZH82L14jp5Sh6OKaO3hO5HN1fY1/RxgsNXvNwjpE3U+R46O0bn2pSePEaIszDaBht+wyla8QNhEAI81w1E81T8/E3woL7w9Zwm2E6f03x/Lzomfkl+phsaQLjWK3nIoS+F7CP6HXxMPbR6jiDMGPfjXNrv77h9eF0A3p8LNiPJ7ohaL18azEWzWfNcixyX7Y8eITuk7jzTgghJSF9nzC5rBpf1RigYtaVsfk5IFTszXW0mZ76bWmQgif0bokXYfY0jP17jUjQoGiieWkhwmRc9JoExx7dX2NfSCtoLFXjFWrQJEbejHxIsOydz6ZGzwuPE2G2fYbSjcQN5wWY18pCJE/R47fdH+Y+A7wwnc8gblM8Py/oCWs6JluawDhW67kwiN63OmqAsY3tvmoKi+zb/2m/vsF6bx9N+9X04FiATNOL4/e6IX173m3HoveFNJrS9van902fMEIISdgnLHgyN81sDLxl83M04c8BQRCFt5GVOLZB7a1++4YKXcWXosqyrQwzK340MCqO3Ca63M3+0djo9SqO31Ng5sVriNQ6G7oXzCeyP3NfTXnrLr5aZ+zX/FSTTyPN8D70OWrep+4JsX7yKMiXT9BrEgk3CecpfDzN90c0fwrzPpD7ssQLzo0eUm0RN8A8h83nwqT1fRvdR3R9c1jzfeTt07i+1vWW+7GBitfGsfh48dX2YaEVzmfzsnmsRt7ktj76vvDvORnixTPLASGElIeEhyMLjNfYNhoOr/EJOVu5RqNRdYcO5ckTJ40GvcTk6n4khBCSgk9YcQl6eqTZelLcwM+nWz0NnctTtJepvOTlfiSEEOKTgk8YIYQQQgixQRFGCCGEEJIBHI4khBBCCEmZxH3CgrewkvJVccYpW/smRf2cEB4OM98Ow2v6/mSzpuEc6fQs0x3ot+Bi32wjhBBCiOuk4BNWD8/D5Ymmzr2k578C786bcRHBBbHkHXut5k9qKY8b0wyoE+BPwYD4cefInywz+q1NTFXQl+9vEkIIIcQN0hNhUQEGMQGRgd4e/Ne/bd8sNONG0/BEjj9XkRJAxnxJWviEttXrvTB8iiUguh0IbeuLvvjePIsIU+kFacqw6PZx58gTYXJeKzM+wrzjpQgjhBBCck/CPmFauETEjQ6XYsL8DZ3SmGkbQ3etvu8H0aLFl+xZ8naA/9iPn07ztnp9WPA0wv3tEDuaLzVpJfZpbhjQPPRoD2ucEz+Z+HNUww7N/dVrXh68+LZzQQghhJDckLhPmBQYWjBERA+Wg6FE4zeEVxBPCxAzrokZjl4mtaHpd9W8re5pi4qjyHZ+QPBbr5NmFUE2wdUKxEcvV9w5UiIsiOeFyK47ijBCCCEk76TvE2YIpZA4Mn6jJ6rR86PCzbgmke3wW4u4oEcrsq35nb8gLx5N2/mBRvqW7+SFaEOEefs0v9Xo7zPuHGkRpvJU9fYvE6cII4QQQopAoiKs+e1I3cule6PQw2P+Ntd5JsVGdL2BJ5KCtJWgkiLOW/a/OeiJl8i24e/8+WEgvB3EVHS/nvhR29mGI4OeslYCCfuW6et0ao1jNcz0i/NFIPaNPBl5kPvR4YQQQgjJGwkPRxJCCCGEkCgp+IQRQgghhJAoKfiEEUIIIYQQG00ibMiQIU1GCCEuwvqKEJIXbPUVRRghJLewviKE5AVbfUURRgjJLayvCCF5wVZfUYQRQnIL6ytCSF6w1VdtizB48ZtvTnKZy1zmsiarZdZXPlzmMpfdX26ur4aI/wdO81GoJCJyvQAAAABJRU5ErkJggg==" /></p><p><strong>Figure 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Height velocity SDS (national) from baseline to week 208</strong></p><p>&nbsp;</p><p>Final height data were collected in 24 paediatric patients (18 included in a two-year prospective, open label, randomised, parallel group study and six who had followed the protocol without randomisation). After the initial two-years prospective study, Norditropin continued until final height. At the end of the treatment the majority of the subjects (16/24) achieved a final height within the normal national reference range (&gt; 2 SDS).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>I.v. infusion of Norditropin (33&nbsp;ng/kg/min for 3&nbsp;hours) to nine growth hormone deficient patients, gave the following results: serum half-life of 21.1&plusmn;1.7&nbsp;min., metabolic clearance rate of 2.33&plusmn;0.58&nbsp;mL/kg/min. and a distribution space of 67.6&plusmn;14.6&nbsp;mL/kg.</p><p>&nbsp;</p><p>S.c. injection of Norditropin SimpleXx (Norditropin SimpleXx is the cartridge containing the solution for injection in Norditropin FlexPro) 2.5&nbsp;mg/m<sup>2</sup> in 31 healthy subjects (with endogenous somatropin suppressed by continuous infusion of somatostatin) gave the following results:</p><p>Maximal concentration of human growth hormone (42‑46&nbsp;ng/mL) after approximately 4&nbsp;hours. Thereafter human growth hormone declined with a half-life of approximately 2.6&nbsp;hours.</p><p>In addition the different strengths of Norditropin SimpleXx were demonstrated to be bioequivalent to each other and to Norditropin for reconstitution after subcutaneous injection to healthy subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The general pharmacological effects on the CNS, cardiovascular and respiratory systems following administration of Norditropin SimpleXx with and without forced degradation were investigated in mice and rats; renal function was also evaluated. The degraded product showed no difference in effect when compared with Norditropin SimpleXx and Norditropin. All three preparations showed the expected dose dependent decrease in urine volume and retention of sodium and chloride ions.</p><p>&nbsp;</p><p>In rats, similar pharmacokinetics has been demonstrated between Norditropin SimpleXx and Norditropin. Degraded Norditropin SimpleXx has also been demonstrated to be bioequivalent with Norditropin SimpleXx.</p><p>&nbsp;</p><p>Single and repeated dose toxicity and local tolerance studies of Norditropin SimpleXx or the degraded product did not reveal any toxic effect or damage to the muscle tissue.</p><p>&nbsp;</p><p>The toxicity of poloxamer&nbsp;188 has been tested in mice, rats, rabbits, and dogs and no findings of toxicological relevance were revealed.</p><p>Poloxamer&nbsp;188 was rapidly absorbed from the injection site with no significant retention of the dose at the site of injection. Poloxamer&nbsp;188 was excreted primarily via the urine.</p><p>&nbsp;</p><p>Norditropin SimpleXx is the cartridge containing the solution for injection in Norditropin FlexPro.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Histidine</p><p>Poloxamer&nbsp;188</p><p>Phenol</p><p>Water for injection</p><p>Hydrochloric acid for pH adjustment</p><p>Sodium hydroxide for pH adjustment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
After first opening: Store for a maximum of 4 weeks in a refrigerator (2C – 8C).
Alternatively, the medicinal product may be stored for a maximum of 3 weeks below 25C.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C) in the outer carton, in order to protect it from light. Do not freeze.</p><p>Do not store close to any cooling elements.</p><p>For storage conditions after first opening of the medicinal product, see section 6.3.</p><p>Do not freeze.</p><p>&nbsp;</p><p>When in use, always replace the pen cap on the Norditropin FlexPro pre-filled pen after each injection. Always use a new needle for each injection.</p><p>The needle must not be screwed onto the pre-filled pen when it is not in use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Norditropin FlexPro 5&nbsp;mg/1.5&nbsp;mL</u> is a multidose disposable pre-filled pen, which consists of a cartridge (Type&nbsp;I colourless glass) permanently sealed in a pen-injector made of plastic components and metal springs. The cartridge is closed at the bottom with a rubber stopper (Type&nbsp;I rubber closures) shaped as a plunger and at the top with a laminated rubber stopper (Type&nbsp;I rubber closures) shaped as a disc and sealed with an aluminium cap. The push button on the pen-injector is coloured orange. Pack sizes of 1 pre-filled pen and a multipack with 5 x 1 pre-filled pens. Not all pack sizes may be marketed.</p><p>&nbsp;</p><p><u>Norditropin FlexPro 10&nbsp;mg/1.5&nbsp;mL</u> is a multidose disposable pre-filled pen, which consists of a cartridge (Type&nbsp;I colourless glass) permanently sealed in a pen-injector made of plastic components and metal springs. The cartridge is closed at the bottom with a rubber stopper (Type&nbsp;I rubber closures) shaped as a plunger and at the top with a laminated rubber stopper (Type&nbsp;I rubber closures) shaped as a disc and sealed with an aluminium cap. The push button on the pen-injector is coloured blue. Pack sizes of 1 pre-filled pen and a multipack with 5 x 1 pre-filled pens. Not all pack sizes may be marketed.</p><p>&nbsp;</p><p><u>Norditropin FlexPro 15&nbsp;mg/1.5&nbsp;mL</u> is a multidose disposable pre-filled pen, which consists of a cartridge (Type&nbsp;I colourless glass) permanently sealed in a pen-injector made of plastic components and metal springs. The cartridge is closed at the bottom with a rubber stopper (Type&nbsp;I rubber closures) shaped as a plunger and at the top with a laminated rubber stopper (Type&nbsp;I rubber closures) shaped as a disc and sealed with an aluminium cap. The push button on the pen-injector is coloured green. Pack sizes of 1 pre-filled pen and a multipack with 5 x 1 pre-filled pens. Not all pack sizes may be marketed.</p><p>&nbsp;</p><p>The pre-filled pen is packed in a carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Norditropin FlexPro is a pre-filled pen designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8&nbsp;mm.</p><p>&nbsp;</p><p>Norditropin FlexPro 5&nbsp;mg/1.5&nbsp;mL delivers a maximum of 2.0&nbsp;mg somatropin per dose, in increments of 0.025&nbsp;mg somatropin.</p><p>Norditropin FlexPro 10&nbsp;mg/1.5&nbsp;mL delivers a maximum of 4.0&nbsp;mg somatropin per dose, in increments of 0.050&nbsp;mg somatropin.</p><p>Norditropin Flexpro 15&nbsp;mg/1.5&nbsp;mL delivers a maximum of 8.0&nbsp;mg somatropin per dose, in increments of 0.1&nbsp;mg somatropin.</p><p>&nbsp;</p><p>To ensure proper dosing and avoid injection of air, check the growth hormone flow before the first injection. Do not use Norditropin FlexPro if a drop of growth hormone does not appear at the needle tip. A dose is selected by turning the dose selector, until the desired dose appears at the window of the housing. If the wrong dose is selected, the dose can be corrected by turning the dose selector the opposite way. The push button is pressed to inject the dose.</p><p>&nbsp;</p><p>Norditropin FlexPro should not be shaken vigorously at any time.</p><p>&nbsp;</p><p>Do not use Norditropin FlexPro if the growth hormone solution for injection is cloudy or discoloured. Check this by turning the pen upside down once or twice.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd, Denmark

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>